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CLASSIFICATION OF CLINICALLY DIFFERENT SUBTYPES OF 
MULTIPLE SCLEROSIS 
SUMMARY 
Multiple sclerosis(MS) is an immune-mediated disease of the central nervous system 
(CNS) with heterogeneous clinical presentation and course. Today, revised 
McDonald‟s criteria is the gold standard for MS diagnosis. MS can be confused with 
other neurological diseases. Moreover, there is no absolute criteria for the prediction 
of prognosis of the disease.   
This study focuses on the classification of different clinical subtypes of MS using 
TAU,GFAP,NFL and MOG proteins and clinical data. The aim of this study are 
summarized  as follows: 
 To investigate different candidate protein and clinical data patterns among the 
MS subtypes, CIS samples and control samples. 
  To show that clinical subtypes of MS can be classified using protein data and 
clinical data.  
 To predict the transition between CIS and MS. This study aims to show that 
the prognosis of MS can be predicted using protein and clinical data.  
Protein findings and clinical data of 67 Relapsing Remitting MS (RRMS), 46 
Clinically Isolated Syndrome (CIS), 22 Primary Progressive MS (PPMS) patients 
and 22 control subjects were analyzed in this study. CSFs of patients were collected 
by lumbar puncture (LP) within 3 days of an acute attack. LP was performed before 
the medication. TAU,GFAP,NFL, MOG and MBP protein concentrations of samples 
were determined by Western Blot analysis. Protein bands were scanned by using 
densitometer and scanned protein bands were analyzed by using ImageJ analysis 
software to obtain quantitative measurement [1]. Quantities of proteins were taken as 
colorimetric unit (CU). CU is a numerical value showing the insensitivity of protein 
band concentration, ranged between 0 (most) and 255 (least). Analyzed values were 
linearized and normalized due to loaded total protein concentration. All samples 
were scanned and analyzed with the same standard procedure. After classical 
statistical analysis such as ANOVA, TAU,GFAP, NFL and MOG protein results 
found  to be significantly different among subtypes and control samples (p<0.001). 
Using different classification methods, different clinical subtypes of multiple 
sclerosis were classified according to their protein and clinical data patterns.  
To the best of our knowledge, there are no other studies in the literature that uses 
these patterns to predict the transition from Clinically Isolated Syndrome (CIS) to 
Multiple Sclerosis. The clasification results of protein data showed that when the 
proteins are used together for classification of MS and control samples,  94.25% ± 
6.44 accuracy and 0.97 ± 0.08 area under curve (AUC) was obtained. It is also found 
that control group and CIS patients can be classified using these proteins together 
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with 87.31% ± 12.02 accuracy and 0.93 ± 0.09 AUC. The overall accuracy obtained 
using GFAP-MOG is 74.12% ± 10.77 (AUC=0.79 ± 0.13) between control  group, 
CIS patients and MS patients.  In addition, when used for discriminating PPMS from 
RRMS, TAU-GFAP and MOG provided 93.65% ± 8.35 accuracy and 0.96 ± 0.11 
AUC. 
Although the  sample size is limited, it has been also shown in this study for the first 
time that the transition from CIS to RRMS can be predicted by using TAU protein 
concentration in CSF. The level of TAU protein gave the 76.22% ± 17.15 (AUC = 
0.77 ± 0.24) accuracy for the differentiation of CIS from CIS/RRMS, whereas GFAP 
levels provided the 67.07% ± 11.77 (AUC =0.81 ± 0.13) accuracy for the overall 
classification of CIS, CIS/RRMS and RRMS. 
The overall results are listed as follows:  
1. MS patients, CIS patients, and control group  were classified with 71.43%± 
10.95 accuracy (AUC: 0.82± 0.12),  
2. CIS and control group were classified with accuracy: 87.31%±12.02 (AUC: 
0.93±0.09),  
3. MS and CIS were clasified with 76.51% ±11.15 (AUC: 0.83 ±0.12) accuracy, 
4.  RRMS and PPMS were classified with 95.77% ±6.63 accuracy (AUC: 
0.97±0.08),  
5. MS and control group were classified with 92.64% ±7.15 (AUC: 0.97±0.06) 
accuracy.  
6. Transition from CIS to RRMS was predicted with 86.45%  ±12.6 (AUC: 
0.89±0.19) accuracy.  
This is a novel study using computer aided classification methods with protein and 
clinical data for diagnostic and prognostic purposes in predicting clinical subtypes of 
MS and predicting transition between subtypes. In future studies, sample size should 
be increased, and new biomarkers should be tested. For better classification results, 
other classification methods can be used. In addition, the parameters of classification 
algorithms can be fine-tuned for better classification performance. A hierarchical 
model can be applied for overall classification of clinical subtypes of MS/CIS 
patients and control group.  
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MULTIPL SKLEROZ HASTALIĞININ FARKLI KLĠNĠK ALTTĠPLERĠNĠN 
SINIFLANDIRILMASI 
ÖZET 
Multipl Skleroz farklı klinik özelliklere sahip farklı altgrupları olan, merkezi sinir 
sisteminin bağışıklık sistemi merkezli bir hastalığıdır. Günümüzde MS teşhisi 
koymak için gözden geçirilmiş McDonalds Kriterleri yaygın bir biçimde 
kullanılmaktadır. Ancak MS diğer sinir sistemi hastalıklarıyla karıştırılabilmektedir. 
Ayrıca, hastalığın prognozunu tayin etmekte kullanılan geçerli bir kriter listesi 
yoktur. 
Bu çalışma TAU, GFAP, NFL ve MOG proteinlerini ve klinik verileri kullanarak 
MS‟in farklı klinik alttiplerinin sınıflandırılmasına odaklanmaktadır. Bu çalışmada 
yapılması amaçlananlar aşağıdaki şekilde özetlenebilir: 
 MS örnekleri, CIS örnekleri ve kontrol grubu arasında farklı aday proteinlerin 
ve klinik veri örüntülerinin araştırılması, 
 MS‟in farklı klinik alttiplerinin protein verileri kullanılarak 
sınıflandırılabileceğinin gösterilmesi, 
 CIS‟dan kesin MS‟e geçişin (prognoz) tahmin edilmesi. Bu çalışma, bu 
tahminle  MS‟in prognozunun protein verileri ve klinik veriler kullanılarak 
tahmin edilebileceğini göstermeyi amaçlamaktadır.  
 
Bu çalışmada 67 RRMS, 46 CIS, 22 PPMS ve 22 kontrol (MS olmayan) örneğinin 
protein ve klinik verileri incelenmiştir. Bu çalışma için kullanılan protein verileri, 
hastaların BOS örneklerinden elde edilmiştir. Hastaların BOS örnekleri bir ataktan 
sonraki 3 gün içinde lomber ponksiyon (LP) yöntemiyle elde edilmiştir. LP ilaç 
kullanımından önce gerçekleştirilmiştir. Örneklerin TAU, GFAP, NFL, MOG ve 
MBP protein konsantrasyonları Western Blot yöntemiyle tayin edilmiştir. Protein 
bantları densitometre kullanılarak taranmıştır ve taranan protein bantları, niceliksel 
bir ölçüm elde edilebilmesi için ImageJ programı ile analiz edilmiştir. Protein 
miktarları kolorimetrik birim (CU) olarak elde edilmiştir. CU protein bant 
konsantrasyonunun yoğunluğunu gösteren ve 0 ile 255 arasında değer alan bir sayısal 
değerdir. Analiz edilmiş değerler yüklenen toplam protein konsantrasyonuna göre 
doğrusallaştırılmış ve normalize edilmiştir. Tüm proteinler aynı prosedür kullanılarak 
taranmış ve analiz edilmiştir. ANOVA gibi klasik istatistiksel analizler sonucunda 
TAU, GFAP, NFL ve MOG protein seviyelerinin farklı alttipler ve kontrol örnekleri 
arasında anlamlı bir farklılık gösterdiği bulunmuştur (p<0.001). Farklı sınıflandırma 
yöntemleri kullanılarak, MS‟in farklı klinik alttpleri protein verileri ve klinik verilere 
göre sınıflandırılmışlardır. 
 
Ayrıca, bu çalışmada literatürde ilk kez CIS‟tan MS‟e geçiş bu klinik veri ve protein 
verilerinin örüntüleri kullanılarak gösterilmiştir.  
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Sınıflandırma için, 6 yöntem karşılaştırılmıştır: kNN, Bayes Ağları, Decorate, Karar 
Ağaçları, Rasgele Ağaç ve AdaBoost. Ayrıca sınıflandırmalar aşağıdaki veri 
altgruplarıyla gerçekleştirilmiştir: 
 Sadece protein verileriyle, 
 Protein verileri üzerinde temel bileşenler analizi uygulandıktan sonra, 
 Protein verileri ve klinik verilerle, 
 Tüm veriler üzerinde temel bileşenler analizi uygulandıktan sonra, 
 Bilgi Kazancı yöntemiyle özellik seçimi yapıldıktan sonra. 
 
Protein verileriyle yapılan testlerin sonuçlarına göre, tüm proteinler kullanılarak MS 
hastaları ve Kontrol grubu 94.25% ± 6.44 (AUC=0.97 ± 0.08) doğrulukla 
sınıflandırılmıştır. Kontrol grubu ve CIS hastalarının sınıflandırılması ise aynı 
protein grubuyla 87.31% ± 12 (AUC= 0.93 ± 0.09) doğrulukla gerçekleşmiştir.  
 
GFAP-MOG proteinleri kullanılarak, MS hastaları, CIS hastaları ve kontrol grubu 
%74.66 (AUC = 0.73) doğrulukla sınıflandırılmıştır. Buna ek olarak, PPMS ve 
RRMS 'in sınıflandırılması TAU-GFAP ve MOG proteinleri tarafından 93.65% ± 
8.35 (AUC= 0.96 ± 0.11) doğrulukla elde edilmiştir.  
 
Bu çalışmada veri boyutunun sınırlı olmasına karşın, CIS'tan RRMS'e geçişin TAU 
proteini kullanılarak öngörülebileceği gösterilmiştir. TAU protein seviyesi CIS'tan 
CISRR'ye geçişi 76.22% ± 17.15 (AUC = 0.77 ± 0.24) doğrulukla tahmin etmiştir. 
CIS, CISRR ve RRMS'in sınıflandırılması ise GFAP proteini kullanılarak 67.07% ± 
11.77 (AUC =0.81 ± 0.13) doğrulukla elde edilmiştir. 
 
Tüm sınıflandırma yöntemlerinin ve tüm veri altgruplarının sonuçlarına bakıldığında: 
1. MS hastaları, CIS hastaları ve kontrol grubu arasındaki 71.43%± 10.95  
(AUC: 0.82± 0.12) doğrulukla,   
2. CIS ve Kontrol grubu arasındaki sınıflandırma 87.31%±12.02 (AUC: 0.93±0.09) 
doğrulukla,  
3. MS ve CIS arasındaki sınıflandırma 76.51% ±11.15 (AUC: 0.83 ±0.12) 
doğrulukla, 
4. RRMS ve PPMS arasındaki sınıflandırma 95.77% ±6.63 (AUC: 0.97±0.08) 
doğrulukla,  
5. MS ve Kontrol grubu arasındaki sınıflandırma 92.64% ±7.15 (AUC: 0.97±0.06) 
doğrulukla,  
6. CIS grubundan RRMS grubuna geçiş 86.45%  ±12.6 (AUC: 0.89±0.19) 
doğrulukla tahmin edilmiştir.  
 
Bu çalışma, MS‟in klinik alttiplerinin tanısı ve prognozunu ve farklı alttipler arası 
geçişi tahmin etmek için bu protein ve klinik verileri ve bilgisayar destekli 
sınıflandırma yöntemlerini kullanan ilk çalışmadır. Çalışmaların devamında örnek 
sayısı arttırılmalıdır. Ayrıca farklı sınıflandırma yöntemlerinin denenmesi de 
gereklidir. Sınıflandırma yöntemlerinin parametrelerinin optimizasyonu da daha iyi 
sonuçlar vermesi beklenmektedir. MS hastaları, CIS hastaları ve kontrol grubunun 
sınıflandırılması için hiyerarşik bir model uygulanabilir. 
 
  
 
1 
1.  INTRODUCTION 
Multiple Sclerosis (MS) is a neuroinflammatory, demyelinating disease with an 
unknown etiology. MS is a very complex and hard-to-diagnose disease. To cope with 
that, several diagnostic criteria are proposed. Today, revised McDonald‟s criteria is 
the gold standard for diagnosis of MS. In recent years, there are extensive studies 
aiming the discovery of novel biomarker(s) for MS diagnosis.  Yet, there is no 
biomarker with sufficient specificity or sensitivity for MS diagnosis   
MS has an autoimmune nature which is caused by both genetic and environmental 
factors, and it is clinically highly heterogeneous with respect to both clinical course 
and pathological mechanisms [2-3]. There are different subtypes of MS which may 
transform from one subtype to another over time depending on the patterns of 
progressions and frequency of symptoms [4]. Complex nature of the disease requires 
reliable diagnostic tools to identify and characterize MS subtypes [5] 
The symptoms of MS can be easily confused by the symptoms of other neurological 
diseases such as Neurobehcet‟s Disease, Lyme disease [6-7]. In addition, it is not 
possible to predict whether a CIS patient will become a MS patient. Furthermore, 
there is no certain way to determine the prognosis of disease, i.e. whether it will 
become progressive. Early prediction of prognosis is important because early 
prediction of outcome can help to the modification of the treatment process on behalf 
of patient.   
Machine learning and pattern recognition methods provide a wide set of tools in the 
area of medical decision making, solution of diagnostic and prognostic problems in 
medicine. In addition, there are various biological applications where machine 
learning  methods are applied for information extraction from data [8]. 
The primary aims of this study are as follows: 
1. To investigate the different protein and clinical data patterns among the MS 
subtypes, CIS samples and control samples.  
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2. To show that clinical subtypes of MS can be classified using protein data and 
clinical data.  
3. To predict the CIS-MS transition.  
4. To show that the MS prognosis can be predicted using protein and clinical 
data.  
In this study, CSF findings and clinical data of 67 RRMS, 46 CIS, 22 PPMS patients 
and 22 control subjects were analyzed for the classification of clinically different 
subtypes of MS.  The accuracy of the classification is investigated by ROC analysis 
using 10-fold cross validation method. 
This thesis is organized as follows: 
 Second chapter covers information about Multiple Sclerosis 
 Third chapter covers information about properties of data, preprocessing 
methods applied to data, and classification methods used for the 
classification of different clinical subtypes of MS 
 Fourth chapter gives results of statistical analysis and classification methods 
  Fifth chapter discusses the findings from this work and discusses future 
improvements. 
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2.  MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system 
(CNS) with heterogeneous clinical presentation and course. Not only MS may 
change between various forms over time, but also the clinical symptoms of these 
forms may be very similar. According to current data, MS is an immune-mediated 
disease of the CNS, with both inﬂammatory and degenerative features [9]. It is 
characterized by recurring relapses and progression that appear multifocal white 
matter and within the lesions [9-11]. The destruction of oligodendrocytes, neurons 
and axons play important role in the pathogenesis of MS [12-15]. 
Studies on MS shows that different patient groups may have different disease courses 
and onset of irreversible disability change. Onset of irreversible disability may be 
later for: females, younger patients, patients with an onset of RR course, patients 
with complete recovery from the first neurological episode; with a low number of 
relapses during the first years of the disease; and those with longer periods of time 
between the first two attacks. In RR patients there are three parameters that shows 
the higher probability for rapid progression to irreversible disability: 1) the late onset 
MS, 2) an incomplete recovery from the first relapse,  and 3) a high number of 
relapses during the first 5 years of MS [16]. 
RR and Progressive MS show differences in gender, onset age, initial symptoms, and 
time from onset to irreversible disability. But RR and progressive MS show no 
difference in time course of disability accumulation from assignment to a given 
disability score to a higher score [17]. 
2.1 Immunopathogenesis of MS 
Recent studies have showed the role of immune cells other than CD4
+
 type-1 T 
helper cells in MS, causing a change in the idea that MS is a CD4
+
 type 1 T helper 
cells mediated autoimmune disorder. Now it is known that the immune response in 
MS is mediated by various immune cells that target brain antigens and the clonal 
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expansion of lymphocytes and the antigen-driven maturation of the B-cell receptors  
are also a part of  T- and B-cell responses in MS patients' brains [18].  
Environmental and genetic factors could effect the permeability of Blood-Brain-
Barrier to the T cells and demyelinating antibodies. Activated T cells in the CNS 
begin to produce  proinflammatory cytokines like IFN- and TNF-, that increase the 
expression of surface molecules of lymphocytes and antigen presenting cells [19]. 
 
Figure 2.1: Immunopathogenesis of MS[18] 
2.2 Symptoms of MS 
The first symptoms of MS are usually visual loss or double vision, nystagmus, 
sensory, and motor signs and symptoms, but a variety of symptoms can be seen. 
Some cases may show no symptoms and/or no disability, others may have a mild 
prognosis or have full-symptomatic MS and severe disability. In progressive cases, 
some cognitive impairment may be observed. This variety of symptomatic changes 
makes MS very difficult to diagnose and predict its prognosis [20]. 
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2.3 Diagnosis of MS 
Diagnosis of MS is a very complicated and difficult issue because of the variety of 
symptoms. Furthermore, similar symptoms can be observed in other neurological 
diseases. In addition, there is not a single test to confirm MS, but there are series of 
criteria that are accepted by MS Society. These criteria include a group of clinical 
and radiological findings. Before 2001,  Poser Criteria was used and in 2001 
McDonald‟s Criteria was accepted [21]. 
2.4 Epidemiology of MS 
MS is more common in northern Europe. The ratio of MS patients in Turkey is 
estimated as 34 per 100000 [22]. Female: Male ratio is two to three times. The 
disease onset age is typically early adulthood (ages between 20- 40) [23]. For 
Europe, the total estimated prevalence rate of MS is 83 per 100000 with higher rates 
in northern countries, and mean annual MS incidence rate is 4.3 cases per 100 000 
[24]. 
2.5 Subtypes of MS 
There are different clinical MS subtypes that may show different progression and 
symptoms of the disease, shown in Figure 2.2. In addition, disease course can change 
from a subtype to another in years, according to the progression of symptoms.  
2.5.1 Relapsing – Remitting MS (RRMS) 
RRMS is the most common form of MS in the onset of disease. RRMS is 
characterized by the acute attacks (relapses) and following total or partial remissions. 
The disease is continuous between the attacks, and relapses are unpredictable. 
Furthermore, full remission may not be obtained after some relapses. RRMS usually 
turn into secondary progressive MS form as the duration of disease increases [25]. 
2.5.2 Primary Progressive MS (PPMS) 
Progression in PPMS is continuous from the beginning. There can be stable time 
periods, in which no new signs of disease activity is seen. 10–15% of all MS patients 
are in this group, and it tends to occur in late onset. Usually disease progression 
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continues until death. The female to male ratio is equal in this group, unlike other 
forms [25].  
2.5.3 Secondary Progressive MS (SPMS) 
This form of MS starts as a RRMS and becomes progressive after 5-6 years.  Attack 
increases the level of disability [25]. 
2.5.4 Progressive – Relapsing MS (PRMS) 
This uncommon form (about 5%) is progressive from the onset with superimposed 
relapses [25]. 
 
 
Figure 2.2: MS Subtypes 
2.6 Clinically Isolated Syndrome (CIS)  
In some patients, MS-like symptoms occur but they do not fulfill the diagnostic 
criteria. Some of these patients develop typical MS later on (5 years).The clinical 
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onset starts with a monoregional involvement of CNS. In some cases of CIS, MRI 
may reveal polyregional involvement of the CNS, in others; the disease will be 
limited to the corresponding anatomic site, remaining monoregional [9].  
2.7 Prognostic Factors in MS 
There are different prognostic factors that have different predictive values for the 
diagnosis and prognosis of MS. In this study, the dataset used has 4 proteins and 17 
clinical features of different subtypes of MS.  
2.8 Biomarkers in MS 
Complex diseases are hard to diagnose, and their diagnosis requires specific 
biomarkers. In MS, proteomic studies aim finding new biomarkers in order to help 
the clinicians to diagnosis and predict prognosis of MS. Here, TAU, MOG, GFAP 
and NFL were used as potential biomarkers for the classification of clinical MS 
subtypes. 
2.8.1 TAU Protein in MS 
TAU play an important role in assembly of microtubules of axons. TAU can be used 
as a biomarker for monitoring neuroaxonal damage. The combination of increased 
NFH and TAU protein levels was more speciﬁc than MRI changes for the prediction 
of transition from CIS to RRMS [26]. Also, TAU protein levels can be used  to 
predict of disease progression or transition from RRMS to PPMS [27].  
2.8.2 Myelin Oligodendrocyte Glycoprotein (MOG) in MS 
MOG plays a role in the structure of myelin sheath and oligodendrocyte. Antibodies 
of  myelin-oligodendrocyte-glycoprotein (MOG), which is exclusively localized on 
the surface of myelin sheaths and oligodendrocytes, and myelin basic protein (MBP), 
have been suggested to predict future disease progression in patients with CIS [28]. 
2.8.3 Glial Fibrillary Acidic Protein (GFAP) in MS 
GFAP is an intermediate filament protein expressed in CNS cells. It was reported 
that patients with major disability showed higher GFAP concentrations in the CSF 
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than patients with low disability [29]. Therefore, GFAP may serve as a biomarker for 
disease progression, probably showing the increasing rate of astrogliosis [26].  
2.8.4 Neurofilament Light Chain (NFL) in MS 
Neurofilaments consist of three parts: a light chain (NFL), an intermediate chain 
(NF-M), and a heavy chain (NF-H). The levels of CSF neuroﬁlaments may have 
some predictive value in patients with CIS (light chain) and RRMS (heavy chain) 
[30]. 
2.8.5 Myelin Basic Protein (MBG) in MS 
MBP is a main functional protein in the myelination process of nerves in the CNS. 
Various forms of MBP with splice forms and post translational modifications are 
found in CSF and CNS space [31-33]. In this study, 14 patients in RRMS, 7 patients 
in CIS, 1 patient in PPMS group and 6 control samples have MBP in their CSF 
samples. These results did not show any significant difference (p>0.05). There may 
be post transitionally modified variants of MBP, which is more abundant in CSF. In 
addition to this MBP isoform, other MBP forms should be studied and their 
differences can be better investigated in future studies. 
2.9 Clinical Data in MS 
In this part, the clinical features in the dataset used in this study and their differences 
between different clinical subtypes of MS are explained: 
2.9.1 MR/T1: 
Black holes on T1 represent lesions with extensive structural loss.  They develop if 
lesions are larger, have a lower MT ratio during enhancement or are ring-enhancing 
[34]. Truyen and van Walderveen described a significant correlation of change in the 
EDSS and change in hypo intense-lesion volume in T1-weighted scans in SPMS, but 
no correlation was found in RRMS [35]. 
2.9.2 MR/T2: 
It is known that all new lesions go through a phase of enhancement for 2 - 8 weeks 
and although most lesions get smaller by time, almost all the time a T2 abnormality 
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persists. Several studies have shown that the number and volume of enhancing tissue 
predicts the onset and severity of relapses [34]. 
2.9.3 Gadolinium Enhancement:  
Gadolinium enhanced magnetic resonance imaging (MRI) of the brain shows the 
development of inflammatory lesions in MS by reflecting the blood-brain-barrier 
disturbances [35]. 
2.9.4 Atrophy (cortical and corpus callosum): 
Brain atrophy is a common finding in MS patients. There is a significant correlation 
between brain atrophy and EDSS score in SPMS, but not in RRMS. Furthermore, it 
was found that total brain atrophy was significantly greater in MS patients than in 
healthy controls [36]. Cortical thinning is an early phenomenon in MS that is already 
detectable at clinical onset. It correlates with clinical disability [37].  
2.9.5 Family history (MS in family): 
Familial and twin studies showed that, risk of MS development increases if there is 
any MS patient among parents or siblings [38]. In addition, familial aggregation of 
MS is genetically determined, not by environmental factors [39]. However, the 
category of MS suffered by the patient is not predictive of the MS phenotype of an 
affected relative [40]. 
2.9.6 Family history ( autoimmune diseases in family): 
Broadley et. al. showed an excess rate of autoimmune disease within first-degree 
relatives of probands with multiple sclerosis [41]. 
2.9.7 Autoimmune diseases in self: 
There was no increase in autoimmune disease within patients with multiple sclerosis 
themselves when compared with the controls or population data [41]. 
2.9.8 Gender: 
The prevalence of multiple sclerosis (MS) is much greater in women [42].  However, 
women had a significantly longer survival time in the disease [43]. When comparing 
RRMS and SPMS patients, gender distribution showed difference; a higher 
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proportion of females RRMS than in SPMS [17]. The female propensity seen in 
RRMS is absent in PPMS[44].  
2.9.9 Onset age: 
Progressive onset patients tend to be older than patients with RRMS onset [40].  
PPMS tends to have a later onset [44]. The prognosis was significantly worse in 
patients with the age at onset over 25. Also, median survival time was 11 years 
shorter in patients with the age at onset over 25 than the patients with earlier onset. 
Later onset age was also a predictor of a poor outcome in RRMS patients [43] . 
2.9.10 Duration of MS: 
The cumulative probabilities of survival over 40 years' period were 22.2% in patients 
with PP and 44.7% in patients with RR disease course. Median survival time in RR 
patients is 38 years whereas progressive patients  have survived 19 and 21 years 
shorter [43].   
2.9.11 EDSS: 
EDSS score at 5 years in patients with PPMS is a strong predictor of the disease 
outcome. The shorter time to reach EDSS 6 was found to be related to the worse 
outcome in patients with RR [43]. Patients developing a progressive disease course 
had signiﬁcantly higher EDSS scores at baseline than patients who remained RR [45]  
2.9.12 CSF/Serum  protein and glucose: 
Low CSF glucose (CSF/serum glucose ratio) and high total CSF protein content 
shows an infectious  situation [46]. For this reason, glucose (CSF-to-serum ratio) and 
Total CSF protein by are used for confirmation MS [26]. 
2.9.13 Oligoclonal Band: 
The proportion of being OCB-positive and OCB-negative, or the number of OCB 
show no difference  between progressive and RRMS patients [45]. 
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3.  METHODS 
In computer-aided diagnosis, machine learning techniques have been widely applied 
to learn hypothesis from diagnosed samples in order to assist the medical experts in 
making diagnosis [47]. Methods for obtaining the results in machine learning 
approaches used various classifications for medical reasoning. 
In this section, statistical/classification methods used in this study and data 
characteristics are explained. 
3.1 Statistical Methods 
Classical statistical methods were applied for the analysis of given proteins for the 
classification significance among different clinical subtypes of MS, CIS and control 
subjects. In this work, Weka 3.6 software was used for data preprocessing and 
classification [48], and SPSS (v.18.0) software was used for statistical analysis [49]. 
3.2 Data Characteristics 
This thesis is a part of an ongoing research project of our group, which was 
supported by Istanbul Technical University and Marmara University scientific 
research projects grant (Grant No: SAG-B-030408-0065).  CSF and serum samples 
were obtained during routine diagnostic evaluation of 67 RRMS, 46 CIS, 22 PPMS 
patients at Istanbul University, Cerrahpaşa Faculty of Medicine (CTF), 
Neuroimmunology and Demyelination Service. Patients were diagnosed according to 
McDonald‟s (2001) and revised McDonald‟s criteria (2005). Diagnosis was based on 
radiological findings (brain MRI and CT), clinical findings and oligoclonal band 
formation in the CSFs of patients. Samples were collected before any treatment and 
medication. Female to male ratio was 1.9:1 (104:53). Control group included 22 
patients suffering from other neurological diseases (OND) like neurobehçet‟s 
disease, polyneuropaty, sarcoidosis, apoplexy (n=11), and a non-inflammatory 
subgroup suffering from migraine (n=11). Ages and genders of the control group 
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were matched with the patient groups. The CSFs were obtained from the patients by 
lumbar puncture (LP). CIS group comprised of two additional subgroups; CIS 
subgroup (remaining as CIS in five years) and CIS/RR subgroup(transition from CIS  
to RRMS within five years). The protocol was approved by the ethics review 
committee of the CTF, Istanbul University for research ethics, oral and written 
information was given to the patients and confirmed consent in writing was received 
before inclusion into the study. 
CSFs of patients were collected by LP within 3 days of an acute attack. LP was 
performed before the medication. TAU,GFAP,NFL, MOG and MBP protein 
concentrations of samples were determined by Western Blot analysis. Protein bands 
were scanned by using densitometer and scanned protein bands were analyzed by 
using ImageJ analysis software to obtain quantitative measurement. Quantities of 
proteins were taken as colorimetric unit (CU). CU is a numerical value showing the 
insensitivity of protein band concentration, ranged between 0 (most) and 255 (least). 
Analyzed values were linearized and normalized due to loaded total protein 
concentration. All samples were scanned and analyzed with the same standard 
procedure. 
3.3 Preprocessing 
Data contained missing values, and features were in different scales. Different 
methods for handling missing values such as Multiple Imputation or using median 
were investigated. Since they gave similar results, using mean values were preferred 
for handling missing values due to easiness of application.  
3.3.1 Handling Missing Data  
A common problem in medical data analysis is missing values, and obtaining valid 
estimates a major issue [33]. In data processing, missing values were replaced using 
“ReplaceMissingValues” filter Weka 3.6 [50]. This filter replaces missing values 
with the modes and mean. 
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3.3.2 Normalization of Data 
In addition to the replacement of missing values, data were normalized in order to 
compare the real characteristics of the data sets by bringing them to a common scale. 
“Normalize” filter was used in Weka for normalization of values within [0,1] range.  
3.3.3 Feature Selection        
For feature selection, information gain method was used [51]. For this purpose, 
“InfoGainFeatureEval”  feature selection method was used in Weka. “Ranker” was 
selected as a search method. Default settings in Weka were used.  
3.3.4 Principal Component Analysis(PCA) 
Principal component analysis was applied to data and classification results of PCA-
applied data and original data were compared. 
3.4 Machine Learning Methods 
Computational methods are required to assess the statistical significance of 
biomarkers with the phenotypes of different diseases. Several classification methods 
can be used in this context. Computational methods are also required for reducing the 
biological variation so that, only significant and relevant proteins can be validated by 
biological methods. 
Ensemble learning paradigms train multiple component learners and then combine 
their predictions. Ensemble techniques can signiﬁcantly improve the generalization 
ability of single learners, and therefore ensemble learning has been a hot topic during 
the past years. An ensemble is usually built in two steps: The ﬁrst step is to generate 
multiple component classiﬁers, and the second step is to combine their predictions 
[47]. 
3.4.1 Decision Tree 
In some fields such as medicine, it is preferable not to use black box approaches 
because it is important for the user to understand the classifier and evaluate its results 
[34]. Decision tree divides a complex decision making process into a collection of  
simpler decisions [52]. J48 is a standard decision tree classifier. It is  the 
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implementation of C4.5 algorithm in Weka. J48 uses greedy approach for inducing 
the decision trees for the classification problem given [53]. 
A decision tree offers a representation of the relevant decisions and outcomes. Every 
path in a decision tree from its root to a leaf represents a result, and only meaningful 
results can be kept by pruning [54]. 
3.4.2 Random Forests 
Random forests are a combination of tree predictors such that each tree depends on 
the values of a random vector sampled independently and with the same distribution 
for all trees in the forest [55]. 
Random forest is an ensemble method, which uses two powerful machine-learning 
techniques: bagging and random feature selection adds an additional layer of 
randomness to these techniques. Bagging, which means bootstrap aggregating, uses 
resampling to improve accuracy of predictions [56]. This randomness results in 
better performance of the classifier when compared to other well known classifiers 
such discriminant analysis, support vector machines and neural networks, and also 
improves the robustness of the classifier against overfitting [55]. 
Random forests consist of using randomly selected inputs or combinations of inputs 
at each node to grow each tree while constructing each tree using a different 
bootstrap sample of the data. The simplest random forest with random features is 
formed by selecting a small random group of input variables at each node to split on 
[55]. 
3.4.3 AdaBoost 
Adaboost (Adaptive Boosting) is a very popular boosting algorithm. Boosting is a 
general method for improving the accuracy of classifiers [57]. The main idea of 
Adaboost is focusing on the weak classifiers more than the strong ones. 
3.4.4 kNN 
kNN (k- Nearest Neighbor) algorithm takes the k nearest examples from a reference 
training set and determines the class of the new example according to the majority 
vote of these examples[58]. In this study, k was considered as 5 for all classification 
tests. 
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3.4.5 DECORATE 
Decorate (Diverse Ensemble Creation by Oppositional Relabeling of Artificial 
Training Examples) is an ensemble learner proposed by [59] that uses an existing 
“strong”(giving high accuracy) learner to build an effective diverse sample subset. 
 
3.4.6 Bayesian Networks 
Bayesian Networks (Bayesnet for short), which are used for modeling relations 
between parameters, are generally used in uncertain data environments. If the output 
value of some parameters are known (this is called evidence), Bayesian networks 
provide the probability distribution of the other parameters in the system [60]. 
Bayesian networks (BNs) are a kind of probabilistic graphical models (GMs), which 
are used to represent knowledge about an uncertain domain. The nodes represent a 
random variable whereas the edges represent probabilistic dependencies of the 
corresponding variables. As a result, Bayesian networks combine different theories 
such as graph theory, probability theory, computer science, and statistic [8]. 
3.5 Evaluation Methods 
10-fold cross-validation was used for evaluation of the accuracy and area under ROC 
curve (AUC) [8] analysis. In 10-fold cross-validation, data was partitioned into 10 
folds and each fold was left out of the training process and used as a test set. The 
resulting accuracy was the overall proportion of the accuracies on all folds [8]. AUC 
curve is typically used as a performance measure for machine learning algorithms, 
and higher AUC values correspond to better classification performance [61]. Each 
classifier was run 1000 times using 10-fold cross validation in order to obtain a 
distribution of accuracy and AUC.  
AUC shows hit rate versus false alarm rate. There is a threshold for deciding the 
number of true positives versus false positive in each classification method, such 
that, increasing true positives also increased false alarms. A point on this curve is 
decided depending on the cost of false positives in a given classification method [8]. 
 
 
  
 
16 
 
 
 
 
 
 
  
 
17 
4.  RESULTS                
In this section, results of 13 classifiers, which are obtained using different feature 
subsets, are given and explained.  
The accuracy reported here is the percentage of correctly classified instances. Since 
the class sizes are not balanced, AUC results are used for further evaluation. A good 
classifier should result in a range of AUC index between 0.5 (chance behavior) and 
1.0 (perfect classification performance) for 2 classes [62]. Our study showed that, 
concentrations of TAU, GFAP, NFL, and MOG proteins in CSF can be used as 
biomarkers of MS for prognosis and diagnosis. Here, our aim is not only to compare 
classification methods and results, but also to show that these selected proteins have 
a predictive value per different subtypes of multiple sclerosis.A general view of 
demographic information for patient records are shown in table 4.1.  
Table 4.1: Demographic information of different subtypes of MS, CIS samples and 
control samples. D indicates the duration of the disease, EDSS, expanded 
disease status scale, MR/T1 and MR/T2 indicates the T1 weighted and 
T2 weighted magnetic resonance score of patients showing the lesion 
counts of the patients when the CSF samples obtained. OCB, indicates 
the oligoclonal band formation score of the patient groups. CSF [protein] 
and CSF [glucose] indicates the level of total protein and total glucose in 
the CSF of sample                                 
Subtype D Age EDSS MR/T1 MR/T2 OCB 
CSF 
[protein] 
CSF 
[glucose] 
CIS 1.7±2 31.7±10.3 
0.7 
±0.8 
0,0.3±0.6 2.2±1.2 1.7±0.8 42.6±17.5 
62.7 
±16.7 
CTRL(total) - 39.4±15.1 - - - - 33.8 51.3 
PPMS 
10.7 ± 
7.6 
 40.3± 8 4.4±2.2 0, 1±1.3 2.8±1.3 
1.9 
±0.3 
 36.4  62.9 
RRMS  4.5 ±4.7 33.9±10.1 1.4±1.3 0.4±0.8 2.4±1.2 1.8±0.4 33.1±9.2 63.5±12.4 
CISRR 1.11±0.8 33.1±11.1 0.9±0.7  0.6±0.9 2.8±1 1.9±0.3  50.7 ±23.2 68.3±27.3 
HC - 51 - - - - 32 79 
OND - 38±15.5 - - - - 34.4 42 
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4.1 Results of Statistical Analysis of Clinical Data 
The results of analysis with each feature is given in this section. For this purpose, the 
mean value +/- standard deviation is given per each clinical subset of MS. If 
meaningful, mean value +/- standard deviation of control groups is also given.  
In figure 4.1, mean value and standard deviation of  onset age among different 
subtypes are shown.  
 
Figure 4. 1: Mean value of onset age according to different subtypes. 
In figure 4.2, mean value and standard deviation of  disease duration among 
CIS,RRMS and PPMS are shown.  
  
Figure 4. 2: Mean value of disease duration according to different subtypes. 
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In figure 4.3, mean value and standard deviation of  disease duration among 
CIS,RRMS and PPMS are shown. EDSS tends to increase as the severity of disease 
increases. 
 
 Figure 4. 3: Mean value of EDSS scores according to different subtypes. 
In figure 4.4, mean value and standard deviation of  MR/T1 scores among 
CIS,RRMS and PPMS are shown. MR/T1 findings tend to increase similar to the 
severity of disease. 
 
Figure 4. 4: Mean value of MR/T1 scores according to different subtypes. 
In figure 4.5, mean value and standard deviation of  MR/T2 scores among 
CIS,RRMS and PPMS are shown. 
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 Figure 4. 5: Mean value of MR/T2 scores according to different subtypes. 
In figure 4.6, mean value and standard deviation of  cortical atrophy scores among 
CIS,RRMS and PPMS are shown. 
 
Figure 4. 6: Mean value of Cortical Atrophy scores according to different subtypes. 
In figure 4.7, mean value and standard deviation of  corpus callosum atrophy scores 
among CIS,RRMS and PPMS are shown. In figure 4.8, mean value and standard 
deviation of  gadolinium enhancement scores among CIS,RRMS and PPMS are 
shown. In figure 4.9, mean value and standard deviation of  OCB scores among 
CIS,RRMS and PPMS  and control groups (HC, OND and total control) are shown. 
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Figure 4. 7: Mean value of Corpus Callosum Atrophy scores according to different 
subtypes. 
 
Figure 4. 8: Mean value of Gadolinium Enhancement scores according to different 
subtypes. 
In figure 4.10, mean value and standard deviation of  CSF protein levels among 
CIS,RRMS and PPMS and control groups (HC, OND and total control)  are shown. 
In figure 4.11, mean value and standard deviation of CSF glucose levels among 
CIS,RRMS and PPMS and control groups (HC and OND)  are shown. In figure 4.12, 
mean value and standard deviation of  serum protein levels among CIS,RRMS and 
PPMS and control groups (HC and OND)  are shown. In figure 4.13, mean value and 
standard deviation of  serum glucose levels among CIS,RRMS and PPMS and 
control groups (HC and OND)  are shown. 
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Figure 4. 9: Mean value of OCB scores according to different subtypes. 
 
Figure 4. 10: Mean value of CSF protein levels according to different subtypes. 
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Figure 4. 11: Mean value of CSF glucose levels according to different subtypes. 
 
Figure 4. 12: Mean value of serum protein levels according to different subtypes. 
  
Figure 4. 13: Mean value of serum glucose levels according to different subtypes. 
4.2 Results of Statistical Analysis of Protein Data 
The results of statistical analysis for proteins (ie. ANOVA and PostHoc tests) are 
given in this section. In table 4.2, mean/standard deviation, standard error and 
confidence interval of TAU protein levels among different clinical subtypes, CIS and 
control groups are given. 
In table 4.3, homogenity test results for TAU is given. This Levene's test results are 
not significant (p=0.979). So, the variances are not significantly different, they are 
homogenous.   
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Table 4.2: Descriptives for TAU levels 
 
N Mean Std. Deviation Std. Error 
95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
CIS 37 47,8452 18,61744 3,06069 41,6378 54,0525 
CIS/RR 9 49,5878 16,11484 5,37161 37,2008 61,9747 
OND 11 32,3857 18,10448 5,45871 20,2230 44,5485 
HC 11 37,1254 20,66999 6,23224 23,2391 51,0116 
PP 16 75,5487 16,69612 4,17403 66,6520 84,4454 
RR 66 55,4156 20,92675 2,57590 50,2712 60,5600 
Total 150 52,3159 21,94210 1,79156 48,7758 55,8561 
Table 4.3: Test of homogenity for TAU levels 
Levene Statistic df1 df2 Sig. 
,152 5 144 ,979 
Table 4.4 shows the ANOVA results for TAU levels. There was a significant effect 
of TAU on the classification of subtypes of Multiple Sclerosis, F(5,149) = 8,934,     
p< .001. 
Table 4.4: ANOVA  for TAU levels 
 Sum of Squares df Mean Square F Sig. 
Between Groups 16984,466 5 3396,893 8,934 ,000 
Within Groups 54752,416 144 380,225   
Total 71736,882 149    
In table 4.5, Brown-Forsythe and Welch forms of F-ratio are shown. But since the 
assumption of homogeneity of variance is not broken, these results only approve the 
previous F-ratio.  
Table 4.5: Robust Tests of Equality of Means for TAU 
levels 
 Statistic
a
 df1 df2 Sig. 
Welch 10,010 5 33,590 ,000 
Brown-Forsythe 9,996 5 73,458 ,000 
a. Asymptotically F distributed. 
In table C.1, PostHoc tests for TAU levels are given. A post-hoc test is needed after 
we complete an ANOVA in order to determine which  groups differ from each other. 
In Table 4.6, Tukey post-hoc comparisons of the six subtypes indicate that the PPMS 
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group gave significantly higher TAU levels than all of the other subtypes, p < 
.001.Also, RRMS group is significantly different than OND group according to  
TAU levels (p=0.005). In Table 4.7, mean, standard deviation, standard error and 
confidence interval of GFAP protein levels among different clinical subtypes, CIS 
and control groups are given. In Table 4.8, homogenity test results for GFAP is 
given. This Levene's test results are not significant (p=0.645). So, the variances are 
not significantly different, they are homogenous. Table 4.9 shows the ANOVA 
results for GFAP levels. There was a significant effect of GFAP on the classification 
of subtypes of Multiple Sclerosis, F(6,147) = 11,831, p< .001. 
Table 4.6: Homogeneous Subsets for TAU levels  (Tukey HSD
a,b
 ) 
SUBTYPES 
N 
Subset for alpha = 0.05 
1 2 3 
 
OND 11 32,3857   
HC 11 37,1254 37,1254  
CIS 37 47,8452 47,8452  
CIS/RR 9 49,5878 49,5878  
RR 66  55,4156 55,4156 
PP 16   75,5487 
Sig.  ,155 ,110 ,057 
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 15,090. 
b. The group sizes are unequal. The harmonic mean of the group 
sizes is used. Type I error levels are not guaranteed. 
In Table 4.10, Brown-Forsythe and Welch forms of F-ratio are shown. Since the 
assumption of homogeneity of variance is still valid, these results only approve the 
previous F-ratio. In Table 4.12, mean, standard deviation, standard error and 
confidence interval of NFL protein levels among different clinical subtypes, CIS and 
control groups are given.  In Table 4.13, homogenity test results for NFL is given. 
This Levene's test results are not significant (p=0.540). So, the variances are not 
significantly different, they are homogenous.  Table 4.14 shows the ANOVA results 
for NFL levels. There was a significant effect of NFL on the classification of 
subtypes of Multiple Sclerosis, F(5,141) = 9,399, p< .001.  
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Table 4.7: Descriptives for GFAP levels 
 
N Mean Std. Deviation Std. Error 
95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
CIS 36 24,3389 12,57111 2,09518 20,0854 28,5923 
CIS/RR 9 26,9944 10,16711 3,38904 19,1793 34,8096 
OND 11 17,8855 16,43760 4,95612 6,8426 28,9285 
HC 11 22,0532 18,96609 5,71849 9,3116 34,7948 
PP 16 54,6781 14,10928 3,52732 47,1598 62,1964 
RR 65 32,4468 16,30719 2,02266 28,4061 36,4875 
Total 148 30,6917 17,74134 1,45833 27,8097 33,5737 
Table 4.8: Test of homogenity for GFAP levels 
Levene Statistic df1 df2 Sig. 
,672 5 142 ,645 
Table 4.9: ANOVA  for GFAP levels 
 Sum of Squares df Mean Square F Sig. 
Between Groups 13606,575 5 2721,315 11,831 ,000 
Within Groups 32662,422 142 230,017   
Total 46268,997 147    
Table 4.10: Robust Tests of Equality of Means for GFAP levels 
 Statistic
a
 df1 df2 Sig. 
Welch 12,277 5 33,421 ,000 
Brown-Forsythe 12,079 5 59,352 ,000 
a. Asymptotically F distributed. 
In Table 4.15, Brown-Forsythe and Welch forms of F-ratio are shown. Since the 
assumption of homogeneity of variance is still valid, these results only approve the 
previous F-ratio. In Table C.3, PostHoc tests for NFL levels are given. In Table 4.16, 
Tukey post-hoc comparisons of the six subtypes indicate that the control groups gave 
significantly lower NFL levels than all of the other subtypes, p < .001. In Table 4.17, 
mean, standard deviation, standard error and confidence interval of MOG protein 
levels among different clinical subtypes, CIS and control groups are given. 
 
 
 
  
 
27 
Table 4.11: Homogeneous Subsets for GFAP levels  (Tukey HSD
a,b
 ) 
SUBTYPES 
N 
Subset for alpha = 0.05 
1 2 
 
OND 11 17,8855  
HC 11 22,0532  
CIS 36 24,3389  
CIS/RR 9 26,9944  
RR 65 32,4468  
PP 16  54,6781 
Sig.  ,096 CIS0 
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 15,053. 
b. The group sizes are unequal. The harmonic mean of the group 
sizes is used. Type I error levels are not guaranteed. 
Table 4.12: Descriptives for NFL levels 
 
N Mean Std. Deviation Std. Error 
95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
CIS 34 72,9670 31,61600 5,42210 61,9357 83,9984 
CIS/RR 9 71,1459 18,89123 6,29708 56,6248 85,6670 
OND 11 29,1336 23,15598 6,98179 13,5772 44,6900 
HC 11 36,5886 27,37403 8,25358 18,1985 54,9788 
PP 16 76,7922 16,42632 4,10658 68,0392 85,5452 
RR 61 75,0726 26,40930 3,38136 68,3088 81,8363 
Total 142 67,9735 30,04448 2,52128 62,9891 72,9579 
Table 4.13: Test of homogenity for NFL levels 
Levene Statistic df1 df2 Sig. 
,817 5 136 ,540 
Table 4.14: ANOVA  for NFL levels 
 Sum of Squares Df Mean Square F Sig. 
Between Groups 32685,885 5 6537,177 9,399 ,000 
Within Groups 94590,687 136 695,520   
Total 127276,572 141    
In Table 4.18, homogenity test results for MOG is given. This Levene's test results 
are not significant (p=0.874). So, the variances are not significantly different, they 
are homogenous. Table 4.19 shows the ANOVA results for MOG levels. There was a 
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significant effect of MOG on the classification of subtypes of Multiple Sclerosis, 
F(5,142) = 13,799, p< .001.  
Table 4.15: Robust Tests of Equality of Means for NFL levels 
 Statistic
a
 df1 df2 Sig. 
Welch 10,292 5 34,397 ,000 
Brown-Forsythe 11,203 5 77,253 ,000 
a. Asymptotically F distributed. 
Table 4.16: Homogeneous Subsets for NFL levels  (Tukey HSD
a,b
 ) 
SUBTYPES 
N 
Subset for alpha = 0.05 
1 2 
 
OND 11 29,1336  
HC 11 36,5886  
CIS/RR 9  71,1459 
CIS 34  72,9670 
RR 61  75,0726 
PP 16  76,7922 
Sig.  
,972 
,992 
OND 
11 
29,1336  
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 14,954. 
b. The group sizes are unequal. The harmonic mean of the group 
sizes is used. Type I error levels are not guaranteed. 
Table 4.17: Descriptives for MOG levels 
 
N Mean Std. Deviation Std. Error 
95% Confidence Interval for 
Mean 
Lower Bound Upper Bound 
CIS 36 53,4517 21,90234 3,65039 46,0410 60,8624 
CIS/RR 8 62,8995 16,79427 5,93767 48,8591 76,9399 
OND 10 16,7144 19,06278 6,02818 3,0777 30,3511 
HC 11 21,4639 13,51502 4,07493 12,3844 30,5434 
PP 16 71,1574 17,87176 4,46794 61,6342 80,6806 
RR 62 56,3437 23,06427 2,92916 50,4865 62,2009 
Total 143 52,1856 25,43604 2,12707 47,9807 56,3904 
Table 4.18: Test of homogenity for MOG levels 
Levene Statistic df1 df2 Sig. 
,361 5 137 ,874 
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Table 4.19: ANOVA  for MOG levels 
 Sum of Squares df Mean Square F Sig. 
Between Groups 30770,979 5 6154,196 13,799 ,000 
Within Groups 61101,914 137 445,999   
Total 91872,893 142    
In Table 4.20, Brown-Forsythe and Welch forms of F-ratio are shown. But since the 
assumption of homogeneity of variance is not broken, these results only approve the 
previous F-ratio. In Table C.4, PostHoc tests for MOG levels are given. In Table 
4.21, Tukey post-hoc comparisons of the six subtypes indicate that the control group 
gave significantly lower MOG  levels than all of the other subtypes, p < .001.  
Table 4.20: Robust Tests of Equality of Means for MOG levels 
 Statistic
a
 df1 df2 Sig. 
Welch 20,723 5 32,448 ,000 
Brown-Forsythe 17,924 5 81,424 ,000 
a. Asymptotically F distributed. 
 
Table 4.21: Homogeneous Subsets for MOG levels  (Tukey HSD
a,b
 ) 
SUBTYPES 
N 
Subset for alpha = 0.05 
1 2 
 
OND 10 16,7144  
HC 11 21,4639  
CIS 36  53,4517 
RR 62  56,3437 
CIS/RR 8  62,8995 
PP 16  71,1574 
Sig.  ,991 ,229 
Means for groups in homogeneous subsets are 
displayed. 
a. Uses Harmonic Mean Sample Size = 14,207. 
b. The group sizes are unequal. The harmonic mean 
of the group sizes is used. Type I error levels are not 
guaranteed. 
Figure 4.14 shows the mean and standard deviation of TAU levels among the CIS 
group and CIS/RR group.  
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Figure 4. 14: Mean value of TAU levels between CIS and CIS/RR. 
Figure 4.15 shows the mean and standard deviation of GFAP levels among the CIS 
group and CIS/RR group. Figure 4.16 shows the mean and standard deviation of 
NFL levels among the CIS group and CIS/RR group.  Figure 4.17 shows the mean 
and standard deviation of MOG  levels among the CIS group and CIS/RR group. 
Figure 4.18 shows the mean and standard deviation of TAU levels among different 
clinical subtypes and control groups. 
  
Figure 4. 15: Mean value of serum GFAP between CIS and CIS/RR. 
  
 
31 
 
Figure 4. 16: Mean value of NFL levels between CIS and CIS/RR. 
 
Figure 4. 17: Mean value of MOG levels between CIS and CIS/RR. 
 
Figure 4. 18: Mean value of TAU levels according to different subtypes. 
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Figure 4.19 shows the mean and standard deviation of GFAP levels among different 
clinical subtypes and control groups. 
 
Figure 4. 19: Mean value of GFAP  levels according to different subtypes. 
Figure 4.20 shows the mean and standard deviation of NFL levels among different 
clinical subtypes and control groups. Figure 4.21 shows the mean and standard 
deviation of MOG levels among different clinical subtypes and control groups. 
 
Figure 4. 20: Mean value of NFL levels according to different subtypes. 
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Figure 4. 21: Mean value of MOG levels according to different subtypes. 
4.3 Results of Protein Data                                                            
Different combinations of TAU, GFAP, NFL and MOG were tested and for each 
classifier, only combination that gives the best AUC index is considered. These AUC 
indexes are calculated via accuracy of that classifier for the given combination of 
proteins. When the AUC indexes were the same, protein combination giving AUC 
with smaller variance value is shown here. Different protein combinations being best 
in different classifiers could be interpreted as that each protein has a different 
classification significance for different MS subgroups and/or control groups. 
This study showed that, TAU, GFAP, NFL, MOG proteins can be used together for 
classification of prognosis and diagnosis stages in clinically different subtype of MS 
depending on their concentrations in the CSF. The difference between the mean 
values of these proteins for different MS subtypes can be seen in figure.4.22.   
It is found that control group and CIS patients (Table D.1, Table D.2,Table D.3) can 
be differentiated using these proteins together by with 87.31% ± 12.02 accuracy and 
0.93 ± 0.09 AUC.  
Although our sample size is limited, it was also shown that the transition from CIS to 
RRMS can be best predicted using TAU protein. The CSF samples of these patients 
were taken when they were diagnosed as CIS patients, so the classification results 
proves that TAU protein level in CSF, differentiates the CIS and CIS/RRMS 
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subgroup even the CSF sample obtained when they are diagnosed as CIS. The level 
of TAU protein gives the best accuracy for the differentiation of CIS from 
CIS/RRMS patients (accuracy=76.22% ± 17.15, AUC = 0.77 ± 0.24 (Table 29). 
 
Figure 4. 22: Mean value of biomarkers according to different subtypes shown by a 
radar chart. 
The classification results show that TAU, GFAP and MOG protein levels in CSF 
give the best accuracy for the differentiation of RRMS from CIS/RRMS patients 
(accuracy=84.28% ± 8.21, AUC 0.72±0.26 ) (Table 30).In addition, GFAP protein 
levels in CSF give the best accuracy for the differentiation of RRMS from CIS 
patients (accuracy = 70.57% ± 12.22,  AUC 0.80±0.12) (Table 31). GFAP and NFL 
protein levels in CSF provided the best accuracy for the classification of CIS and MS  
(accuracy =76.72% ± 10.52, AUC =0.82±0.12 ) (Table 32). GFAP levels provided 
the best accuracy for the classification of CIS, CIS/RRMS and RRMS (accuracy 
=67.07% ± 11.77, AUC =0.81 ± 0.13) (Table 33). 
When these proteins are used together for classification of MS and control samples, 
94.25% ± 6.44 accuracy and 0.97 ± 0.08 AUC was obtained (Table D.9, Table D.10, 
Table D.11). In addition, with these proteins PPMS and RRMS subtypes can be 
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classified with 96,4% accuracy (AUC (0.96)) when all the protein data are used 
(Table D.12). The overall accuracy, obtained using GFAP-MOG, is 74.12% ± 10.77 
(AUC=0.79 ± 0.13) between control group, CIS patients and MS patients (Table 
D.13). 
When the classification results of TAU, GFAP, NFL and MOG are considered 
separately, using these proteins provided better results in general (Table 4.22). 
Therefore, using these proteins together gives better results in different groups of 
comparison. 
Table 4.22: Classification Results of protein combinations resulting best AUC 
Classifier AUC (ROC area) Accuracy Proteins used 
CIS vs. CIS/RR 0.77 ± 0.24 76.22 ± 17.15 TAU 
CIS vs. CTRL 0.93 ± 0.09 87.31 ± 12.02 TAU-GFAP-NFL-MOG 
CIS vs. HC 0.90 ± 0.17 90.96 ± 11.62 NFL-MOG 
CIS vs. OND 0.93 ± 0.11 86.30 ± 13.22 TAU-GFAP-MOG 
CIS vs. MS 0.82 ± 0.12 76.72 ± 10.52 GFAP-NFL 
CIS vs. CIS/RR vs. RR 0.81 ± 0.13 67.07 ± 11.77 GFAP 
MS vs. CTRL 0.97 ± 0.08 94.25 ± 6.44 TAU-GFAP-NFL-MOG 
MS vs. HC 0.95 ± 0.14 96.65 ± 5.59 TAU-NFL-MOG 
MS vs. OND 0.98 ± 0.05 95.80 ± 5.94 TAU-GFAP-NFL-MOG 
MS vs. CTRL vs. CIS 0.79 ± 0.13 74.12 ± 10.77 GFAP-MOG 
PP vs. RR 0.96 ± 0.11 93.65 ± 8.35 TAU-GFAP-MOG 
RR vs. CIS 0.80 ± 0.12 70.57 ± 12.22 GFAP 
RR vs. CISRR 0.80 ± 0.20 83.42 ± 8.52 GFAP-NFL 
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4.4 Results of Protein Data and Clinical Data  
In this part, classification results of only protein data (proteins), results of Principle 
Components of  Protein Data,  Results of all features ( protein data and clinical data),  
results of principal components of all features and results of a group of  features that 
are selected using Information Gain Method are presented for each classifier. While 
selecting the features, all features that give positive information gain (that are >0) are 
selected. Six different classification methods are used for each classifier; K-nearest 
neighbors, Decision Tree, Random Forest, AdaBoost, Decorate and Bayesian 
Network.  For all results, accuracy and AUC (AUC) are given together. Highest 
accuracy and AUC values are shown as bold. In addition, resulting features of 
Information Gain Feature Selection method are shown. 
4.4.1 Classification of MS, Control and CIS samples 
In Table E.1, Classification results of MS patients, Total Control group and CIS 
patients are given. Best accuracy is provided by selected features (using InfoGain), 
using Bayesian networks classification method (accuracy: 73.01%± 10.51, AUC:  
0.77±0.13). Best AUC is achieved by selected features using Random Forest 
classification method (accuracy: 71.43± 10.95, AUC:0.82± 0.12). It is important to 
note that the results of feature selection contained protein data. This also shows the 
predictive and differentiative significance of proteins. 
4.4.2 Differentiation of CIS from Control 
In Table E.2, classification results of CIS patients, total control group are given  Best 
accuracy is provided by principal components of protein data using kNN 
classification method (accuracy: 87.45%±12.02, AUC: 0.93±0.10). Best AUC is 
achieved by protein data using kNN classification method(accuracy:  87.31%±12.02,  
AUC: 0.93±0.09)  and by resulting  features of feature selection method, using kNN 
classification method (accuracy 86.06±12.14, AUC: 0.93±0.09).  The results of 
feature selection contained protein data. In Table E.3, Classification results of OND 
Control Subgroup and CIS patients are given. For this classifier, results of feature 
selection only contained one of the proteins. In Table E.4, Classification results of 
Healthy Control group and CIS patients are given. The results of feature selection 
contained protein data. 
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4.4.3 Differentiation of MS from CIS 
 In Table E.5, Classification results of MS patients and CIS patients are given.  
4.4.4 Differentiation of MS from Control 
In Table E.6, Classification results of MS patients and Total Control group are given. 
It is important to note that the results of feature selection contained protein data. This 
also shows the predictive and differentiative significance of proteins. In Table E.7, 
Classification results of MS patients and OND Control subgroup are given. The 
results of feature selection contained only one of the proteins. It is important to note 
that the results of feature selection consists of protein data. So, these proteins are 
solely enough for the differentiation of MS from other neurological diseases. In 
Table E.8, Classification results of MS patients and Healthy Control group are given.  
4.4.5 Classification of MS Subtypes: RR vs. PP 
In Table E.9, Classification results of PPMS patients and RRMS patients are given. 
The results of feature selection contained 3 features of  protein data 
4.4.6 Transition from CIS to MS 
In Table E.10, Classification results of CIS patients and CISRR patients are given. 
Here, the transition from CIS to MS is shown. It is important to note that the results 
of feature selection did not contain any  protein data. This shows that protein data are 
not the best features for the differentiation of transition from CIS to MS. In Table 
E.11, Classification results of CISRR patients, RR patients and CIS patients are 
given  
It is important to note that when looked at the confusion matrix (Table 4.23),CISRR 
patients were not classified correctly (there were no true positive). Six of them were 
classified as RR patients whereas 3 of them were classified as CIS patients. The 
majority of them being classified as RR patients supports the results of transition 
from CIS to MS. Although they were classified as CIS, they would be „misclassified‟ 
as RR at the initial diagnosis.  In Table E.12, Classification results of RRMS  
patients and CISRR patients are given. The results of feature selection contained no 
protein data. In Table 4.24, confusion matrix of classification of CISRR and RR is 
shown (accuracy: 88.16% , AUC:0.89).Although there are no false positives, there 
  
 
38 
are no true positives neither for CISRR patients. This shows that it is difficult to 
differentiate CISRR patients from RR patients using these data.  
In Table 4.25, confusion matrix of classification method giving the best accuracy is 
shown. Here, there are false positives and false negatives for CISRR patients.  
Table 4.23: Confusion Matrix of CIS vs. CISRR vs. RR, all features, Random Forest Classification 
Method ( accuracy: 71.68% , AUC:0.79). 
CIS CISRR RR  
26 0 11 CIS 
3 0 6 CISRR 
10 2 55 RR 
Table 4.24: Confusion Matrix of CISRR vs. RR,feature selection applied,  kNN Classification 
Method. (accuracy: 88.16% , AUC:0.89) 
CISRR RR  
0 9 CISRR 
0 67 RR 
Table 4.25: Confusion Matrix of CISRR vs. RR,feature selection applied,  Random Forest  
Classification Method(accuracy: 90.79 %, AUC: 0.83). 
CISRR RR  
5 4 CISRR 
3 64 RR 
In Table E.13, classification results of RRMS patients and CIS patients are given. Six 
different classification methods are used for this classifier; K-nearest neighbors, 
Decision Tree, Random Forest, AdaBoost, Decorate and Bayesian Network. Also, 
here are presented the results of different feature sets: protein data, principle 
components of protein data, all features (protein data and clinical data), principal 
components of all data and features selected using Information Gain method. While 
selecting the features, all features that give positive information gain (that are >0) are 
selected.  
  
 
39 
In Table 4.26, a sumary of classification results is given. Here, for each clasifier, the 
best AUC is selected and used features and methods are shown. 
Table 4.26: Classification results of features giving best AUC 
Classifier AUC (ROC area) Accuracy Features used 
CIS vs. CIS/RR 0.89±0.19 86.45±12.62 
Autoimmune Disease in Family,   
MR/T1,    OCB,    CSF Protein Level 
CIS vs. CTRL 0.93±0.09 86.06±12.14 
MR/T2, Gadolinium Enhancement, 
TAU, GFAP, NFL, MOG 
CIS vs. HC 0.98±0.07 89.47±11.72 
Duration of MS, Onset Age, 
Autoimmune Disease in Self, 
Autoimmune Disease in Family,  
Atrophy/Cortical, Atrophy/Corpus 
Callosum,  Gadolinium Enhancement, 
TAU, NFL, MOG 
CIS vs. OND 0.95±0.12 89.06±12.06 TAU,GFAP,NFL,MOG (PCA) 
CIS vs. MS 0.83 ±0.12 76.51 ±11.15 All features 
CIS vs. CIS/RR vs. RR 0.81±0.13 63.79±12.17 Duration of MS ,     OCB,  GFAP  
MS vs. CTRL 0.97±0.06 92.64±7.15 TAU,GFAP,NFL,MOG (PCA) 
MS vs. HC 0.96 ±0.09 90.04 ±9.98 All features 
MS vs. OND 0.99±0.04 95.02±5.91 TAU,GFAP,NFL,MOG (PCA) 
MS vs. CTRL vs. CIS 0.82± 0.12 71.43± 10.95 
Duration of MS, EDSS,   OCB, TAU , 
GFAP, NFL , MOG 
PP vs. RR 0.97±0.08 95.77±6.63 TAU,GFAP,NFL,MOG (PCA) 
RR vs. CIS 0.80±0.13 75.35±12.05 Duration of MS, GFAP 
RR vs. CISRR 0.92±0.12 89.77±7.00 
Duration of MS, MS in Family, 
Gadolinium Enhancement, CSF Protein 
Level 
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5.  DISCUSSION AND CONCLUSION 
In this study, different clinical subtypes of multiple sclerosis are classified according 
to their protein and clinical data patterns with different classification methods.  
To the best of our knowledge, it is the first study in the literature where the transition 
from Clinically Isolated Syndrome to Multiple Sclerosis is predicted using these 
patterns. 
For the classification, 6 different methods were compared: KNN, Bayesian 
Networks, DECORATE, Decision Tree, Adaboost and Random Forest. Furthermore, 
following features are used for classification; 
 Only protein data 
 Principle Component Analysis on protein data 
 All Features including protein data and clinical data 
 Principal Component Analysis on all features 
 Feature Selection according to Information Gain. 
Here, each classification problem gives best results in different classification 
methods and usually using different features. This shows that each classification 
problem has different distribution for the features, and these classification problems 
should be handled separately. A hierarchical model should be applied for overall 
classification of clinical subtypes of MS and CIS patients and control group. Of 
course, number of samples is one of the most important criteria. Since the number of 
samples is relatively small, making a generalization would be difficult.  
The results of PCA do not differ very much from the original results (even 
sometimes worse than the original results). This shows that features are independent 
from each other and correlation between features is low. In addition, the information 
gain based feature selection method selects the proteins as relevant features. It can be 
deduced that these selected proteins are good candidate biomarkers for the 
classification of clinically different subtypes of MS. 
The most remarkable point for the clasification using proteins is that the candidate 
protein proteins gave more significant results when they were investigated together 
  
 
42 
in a sample. The results of classification showed that concentration levels of TAU, 
GFAP, NFL and MOG proteins in CSF should be considered together to use as 
biomarker for the prediction of diagnosis and prognosis of MS. In addition, the 
patients whose diagnose changes CIS to RRMS depending on the new attacks and 
lesions in the brain can be predicted by analyzing TAU protein level in CSF. This is 
a novel study using computer aided classification methods and these protein and 
clinical data together for diagnostic and prognostic purposes in predicting clinical 
subtypes of MS and predicting transition between subtypes.  
In conclusion, this is the first study predicting transition from CIS to definite MS 
using TAU, GFAP, NFL and MOG proteins and clinical data patterns. Furthermore, 
this is the first study classifying the different subtypes of multiple sclerosis applying 
computer aided methods to given subset of proteins and clinical data.  
For future studies, sample size should be increased for the generalization of classifier 
model to be implemented. In addition, different classification methods should be 
applied. The optimization of parameters of classification methods could give better 
results. Outlier detection and looking at the properties of data could be applied. 
In addition, new identified protein biomarkers from proteome studies should be 
tested and these results need the comparison with other MS patient groups. 
In order to compare the classification results, the error rates should be reduced. For 
this purpose, bootstrapping or leave-one-out method should be applied as cross-
validation method instead of 10-fold cross validation. 
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APPENDIX A. Explanation of scoring system of parameters  
Gender:  1:male 0:Female 
Autoimmune Disease in self: 1: Yes 0:No x:not known 
Autoimmune Disease in family: 1: Yes 0:No x:not known 
Autoimmune Disease in family: 1: Yes 0:No x:not known 
Oligoclonal Band: 1:positive 2:negative 3:not checked     4:checked,but 
no data 5:other  6:not known 
EDSS:  
The functional systems(FS) are:  pyramidal, cerebellar, brainstem, sensory, bowel 
and bladder, visual, cerebral and other. 
0.0: Normal Neurological Exam 
1.0: No disability, minimal signs on 1 FS 
1.5: No disability, minimal signs on 2 of 7 FS 
2.0: Minimal disability in 1 of 7 FS 
2.5: Minimal disability in 2 FS 
3.0: Moderate disability in 1 FS; or mild disability in 3 - 4 FS, though fully 
ambulatory 
3.5: Fully ambulatory but with moderate disability in 1 FS and mild disability in 1 or 
2 FS; or moderate disability in 2 FS; or mild disability in 5 FS 
4.0: Fully ambulatory without aid, up and about 12hrs a day despite relatively severe 
disability. Able to walk without aid 500 meters 
4.5: Fully ambulatory without aid, up and about much of day, able to work a full day, 
may otherwise have some limitations of full activity or require minimal assistance. 
Relatively severe disability. Able to walk without aid 300 meters 
5.0: Ambulatory without aid for about 200 meters. Disability impairs full daily 
activities 
5.5: Ambulatory for 100 meters, disability precludes full daily activities 
6.0: Intermittent or unilateral constant assistance (cane, crutch or brace) required to 
walk 100 meters with or without resting 
6.5: Constant bilateral support (cane, crutch or braces) required to walk 20 meters 
without resting 
7.0: Unable to walk beyond 5 meters even with aid, essentially restricted to 
wheelchair, wheels self, transfers alone; active in wheelchair about 12 hours a day 
7.5: Unable to take more than a few steps, restricted to wheelchair, may need aid to 
transfer; wheels self, but may require motorized chair for full day's activities 
8.0: Essentially restricted to bed, chair, or wheelchair, but may be out of bed much of 
day; retains self care functions, generally effective use of arms 
8.5: Essentially restricted to bed much of day, some effective use of arms, retains 
some self care functions 
9.0: Helpless bed patient, can communicate and eat 
9.5: Unable to communicate effectively or eat/swallow 
10.0: Death due to MS 
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APPENDIX B. List of features  
Feature1: Gender                                                                               
Feature2:Duration of MS                                                                              
Feature3:Onset age                                                                                   
Feature4:MS in Family                                                                             
Feature5:Autoimmune Disease in self                                                                              
Feature6:Autoimmune Disease in family                                         
Feature7:EDSS                                                                                 
Feature8:MR/T1                                                                               
Feature9:MR/T2                                                                                
Feature10: Atrophy / Cortical                                                                              
Feature11: Atrophy / Corpus Callosum                                                                          
Feature12: Gadolinium Enhancement                                                                              
Feature13: OCB                                                                                
Feature14: CSF Protein Level                                                                              
Feature15: CSF Glucose Level                                                                              
Feature16:Serum Protein Level                                                                             
Feature17: Serum Glucose Level                                                                             
Feature18:CSF TAU                                                                             
Feature19:CSF GFAP                                                                              
Feature20:CSF NFL                                                                              
Feature21:CSF MOG 
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APPENDIX C. Results of PostHoc  Analysis 
Table C.1: PostHoc Tests for TAU levels  (Tukey HSD) 
(I) 
SUBTYPES 
(J) SUBTYPES Mean 
Difference (I-J) Std. Error Sig. 
 
CIS 
 
CIS/RR -1,74262 7,24732 1,000 
OND 15,45943 6,69644 ,197 
HC 10,71980 6,69644 ,599 
PP -27,70353
*
 5,83442 ,000 
RR -7,57044 HC466 ,412 
CIS/RR 
 
CIS 1,74262 7,24732 1,000 
OND 17,20205 8,76431 ,369 
HC 12,46241 8,76431 ,714 
PP -25,96091
*
 8,12473 ,021 
RR -5,82783 6,92880 ,959 
OND 
 
CIS -15,45943 6,69644 ,197 
CIS/RR -17,20205 8,76431 ,369 
HC -4,73964 8,31456 ,993 
PP -43,16296
*
 7,63741 ,000 
RR -23,02988
*
 6,35035 ,005 
HC 
 
CIS -10,71980 6,69644 ,599 
CIS/RR -12,46241 8,76431 ,714 
OND 4,73964 8,31456 ,993 
PP -38,42332
*
 7,63741 ,000 
RR -18,29024 6,35035 ,051 
PP 
 
CIS 27,70353
*
 5,83442 ,000 
CIS/RR 25,96091
*
 8,12473 ,021 
OND 43,16296
*
 7,63741 ,000 
HC 38,42332
*
 7,63741 ,000 
RR 20,13308
*
 5,43370 ,004 
RR 
 
CIS 7,57044 HC466 ,412 
CIS/RR 5,82783 6,92880 ,959 
OND 23,02988
*
 6,35035 ,005 
HC 18,29024 6,35035 ,051 
PP -20,13308
*
 5,43370 ,004 
*. The mean difference is significant at the 0.05 level. 
 
 
 
  
 
53 
Table C.2: PostHoc Tests for GFAP levels  (Tukey HSD) 
(I) 
SUBTYPES 
(J) SUBTYPES Mean 
Difference (I-J) Std. Error Sig. 
 
CIS 
 
CIS/RR -2,65558 5,65215 ,997 
OND 6,45332 5,22494 ,819 
HC 2,28568 5,22494 ,998 
PP -30,33926
*
 4,55691 ,000 
RR -8,10794 3,15089 ,111 
CIS/RR 
 
CIS 2,65558 5,65215 ,997 
OND 9,10890 6,81675 ,764 
HC 4,94126 6,81675 ,979 
PP -27,68368
*
 6,31930 ,000 
RR -5,45236 5,39409 ,914 
OND 
 
CIS -6,45332 5,22494 ,819 
CIS/RR -9,10890 6,81675 ,764 
HC -4,16764 6,46694 ,987 
PP -36,79258
*
 5,94026 ,000 
RR -14,56125
*
 4,94463 ,043 
HC 
 
CIS -2,28568 5,22494 ,998 
CIS/RR -4,94126 6,81675 ,979 
OND 4,16764 6,46694 ,987 
PP -32,62494
*
 5,94026 ,000 
RR -10,39362 4,94463 ,292 
PP 
 
CIS 30,33926
*
 4,55691 ,000 
CIS/RR 27,68368
*
 6,31930 ,000 
OND 36,79258
*
 5,94026 ,000 
HC 32,62494
*
 5,94026 ,000 
RR 22,23133
*
 4,23259 ,000 
RR 
 
CIS 8,10794 3,15089 ,111 
CIS/RR 5,45236 5,39409 ,914 
OND 14,56125
*
 4,94463 ,043 
HC 10,39362 4,94463 ,292 
PP -22,23133
*
 4,23259 ,000 
*. The mean difference is significant at the 0.05 level. 
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Table C.3: PostHoc Tests for NFL levels  (Tukey HSD) 
(I) 
SUBTYPES 
(J) SUBTYPES Mean 
Difference (I-J) Std. Error Sig. 
 
CIS 
 
CIS/RR 1,82114 9,88617 1,000 
OND 43,83339
*
 9,14798 ,000 
HC 36,37839
*
 9,14798 ,002 
PP -3,82516 7,99540 ,997 
RR -2,10554 5,64433 ,999 
CIS/RR 
 
CIS -1,82114 9,88617 1,000 
OND 42,01225
*
 11,85365 ,007 
HC 34,55725
*
 11,85365 ,047 
PP -5,64630 10,98863 ,996 
RR -3,92668 9,41711 ,998 
OND 
 
CIS -43,83339
*
 9,14798 ,000 
CIS/RR -42,01225
*
 11,85365 ,007 
HC -7,45500 11,24536 ,986 
PP -47,65855
*
 10,32952 ,000 
RR -45,93894
*
 8,63893 ,000 
HC 
 
CIS -36,37839
*
 9,14798 ,002 
CIS/RR -34,55725
*
 11,85365 ,047 
OND 7,45500 11,24536 ,986 
PP -40,20355
*
 10,32952 ,002 
RR -38,48394
*
 8,63893 ,000 
PP 
 
CIS 3,82516 7,99540 ,997 
CIS/RR 5,64630 10,98863 ,996 
OND 47,65855
*
 10,32952 ,000 
HC 40,20355
*
 10,32952 ,002 
RR 1,71961 7,40756 1,000 
RR 
 
CIS 2,10554 5,64433 ,999 
CIS/RR 3,92668 9,41711 ,998 
OND 45,93894
*
 8,63893 ,000 
HC 38,48394
*
 8,63893 ,000 
PP -1,71961 7,40756 1,000 
*. The mean difference is significant at the 0.05 level. 
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Table C.4: PostHoc Tests for MOG levels  (Tukey HSD) 
(I) 
SUBTYPES 
(J) SUBTYPES Mean 
Difference (I-J) Std. Error Sig. 
 
CIS 
 
CIS/RR -9,44778 8,25462 ,862 
OND 36,73732
*
 7,54909 ,000 
HC 31,98781
*
 7,27559 ,000 
PP -17,70572 6,34538 ,065 
RR -2,89199 4,42520 ,987 
CIS/RR 
 
CIS 9,44778 8,25462 ,862 
OND 46,18510
*
 10,01748 ,000 
HC 41,43559
*
 9,81302 ,001 
PP -8,25794 9,14466 ,945 
RR 6,55579 7,93369 ,962 
OND 
 
CIS -36,73732
*
 7,54909 ,000 
CIS/RR -46,18510
*
 10,01748 ,000 
HC -4,74951 9,22742 ,996 
PP -54,44304
*
 8,51322 ,000 
RR -39,62931
*
 7,19677 ,000 
HC 
 
CIS -31,98781
*
 7,27559 ,000 
CIS/RR -41,43559
*
 9,81302 ,001 
OND 4,74951 9,22742 ,996 
PP -49,69353
*
 8,27166 ,000 
RR -34,87980
*
 6,90934 ,000 
PP 
 
CIS 17,70572 6,34538 ,065 
CIS/RR 8,25794 9,14466 ,945 
OND 54,44304
*
 8,51322 ,000 
HC 49,69353
*
 8,27166 ,000 
RR 14,81373 5,92187 ,131 
RR 
 
CIS 2,89199 4,42520 ,987 
CIS/RR -6,55579 7,93369 ,962 
OND 39,62931
*
 7,19677 ,000 
HC 34,87980
*
 6,90934 ,000 
PP -14,81373 5,92187 ,131 
*. The mean difference is significant at the 0.05 level. 
 
 
 
  
 
56 
APPENDIX D. Results of Classification of Protein Data                        
Table D.1: Classification Results of CIS vs. Total Control 
5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) ROC Area (AUC) Accuracy 
All proteins 0.93±0.09 87.31±12.02 
TAU 0.82±0.15 67.78±15.92 
GFAP 0.69±0.21 68.69±15.64 
NFL 0.77±0.22 82.76±13.95 
MOG 0.83±0.18 87.64±12.38 
GFAP-MOG 0.91±0.12 86.36±12.23 
TAU-GFAP 0.82±0.15 75.18±15.62 
GFAP-NFL 0.85±0.14 76.30±14.60 
GFAP-NFL-MOG 0.93±0.10 86.30±11.88 
NFL-MOG 0.86±0.16 90.01±11.10 
TAU-GFAP-MOG 0.90±0.12 85.50±13.30 
TAU-GFAP-NFL 0.86±0.13 78.11±14.18 
TAU-MOG 0.89±0.13 85.91±12.24 
TAU-NFL 0.86±0.14 80.04±13.98 
TAU-NFL-MOG 0.93±0.10 87.50±11.64 
Table D.2: Classification Results of CIS vs. Healthy Control 
5NN 10 fold cross validation, 1000 
run p<0.05 two tailed, paired t-test 
(corrected)   
ROC Area (AUC) Accuracy 
All proteins 0.90±0.17  87.79±12.18  
TAU 0.78±0.20  78.62±10.39  
GFAP 0.74±0.24  75.14±13.40  
NFL 0.81±0.28  82.15±14.14  
MOG 0.85±0.24  88.59±11.92  
GFAP-MOG 0.85±0.23  90.93±11.80  
TAU-GFAP  0.77±0.23  72.99±14.40  
GFAP-NFL 0.77±0.26  82.09±14.37  
GFAP-NFL-MOG 0.89±0.17  88.53±12.44  
NFL-MOG 0.90±0.17  90.96±11.62  
TAU-GFAP-MOG 0.86±0.22  89.06±12.54  
TAU-GFAP-NFL 0.80±0.22  78.31±14.12  
TAU-MOG 0.86±0.22  91.17±11.55  
TAU-NFL 0.83±0.22  81.57±14.42  
TAU-NFL-MOG 0.90±0.17  89.82±12.11  
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Table D.3: Classification Results of CIS vs OND 
5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) 
ROC Area (AUC) Accuracy 
All proteins 0.92±0.11 82.29±12.31 
TAU 0.80±0.20 83.21±11.45 
GFAP 0.55±0.28 75.71±11.22 
NFL 0.74±0.32 79.68±14.37 
MOG 0.88±0.18 88.45±13.26 
GFAP-MOG 0.92±0.11 85.45±12.09 
TAU-GFAP 0.77±0.18 70.79±13.92 
GFAP-NFL 0.82±0.16 72.90±13.69 
GFAP-NFL-MOG 0.92±0.11 85.85±12.49 
NFL-MOG 0.86±0.23 90.50±11.70 
TAU-GFAP-MOG 0.93±0.11 86.30±13.22 
TAU-GFAP-NFL 0.86±0.14 74.83±13.60 
TAU-MOG 0.89±0.21 95.52±6.55 
TAU-NFL 0.85±0.20 81.51±13.86 
TAU-NFL-MOG 0.91±0.12 85.59±12.38 
Table D.4: Classification results for the differentiation of CIS and CIS/RRMS 
 5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) 
ROC Area (AUC) Accuracy 
All proteins 0.68±0.32 83.24±14.19 
TAU 0.77±0.24 76.22±17.15 
GFAP 0.64±0.32 79.52±16.69 
NFL 0.72±0.32 81.13±16.48 
MOG 0.63±0.28 77.01±12.51 
GFAP-MOG 0.69±0.36 79.99±15.64 
TAU-GFAP 0.66±0.34 80.40±17.19 
GFAP-NFL 0.69±0.36 79.99±15.64 
GFAP-NFL-MOG 0.58±0.34 80.46±14.11 
NFL-MOG 0.60±0.32 74.86±12.52 
TAU-GFAP-MOG 0.63±0.35 80.32±15.08 
TAU-GFAP-NFL 0.68±0.33 88.19±12.01 
TAU-MOG 0.73±0.27 78.56±15.62 
TAU-NFL 0.69±0.32 85.74±13.68 
TAU-NFL-MOG 0.68±0.32 83.15±14.12 
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Table D.5: Classification Results of CIS/RRMS vs. RRMS 
5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) 
ROC Area (AUC) Accuracy 
All proteins 0.58±0.23 87.19±5.25 
TAU 0.60±0.20 88.18±4.07 
GFAP 0.66±0.28 84.17±8.54 
NFL 0.51±0.27 88.19±4.05 
MOG 0.65±0.28 85.31±7.24 
GFAP-MOG 0.57±0.25 87.27±6.01 
TAU-GFAP 0.63±0.25 87.97±4.34 
GFAP-NFL 0.80±0.20 83.42±8.52 
GFAP-NFL-MOG 0.61±0.22 84.98±7.17 
NFL-MOG 0.59±0.29 87.10±6.16 
TAU-GFAP-MOG 0.72±0.26 84.28±8.21 
TAU-GFAP-NFL 0.62±0.28 87.28±5.77 
TAU-MOG 0.60±0.29 84.95±7.39 
TAU-NFL 0.56±0.32 86.08±7.16 
TAU-NFL-MOG 0.53±0.25 86.69±5.95 
Table D.6: Classification Results of CIS vs  RRMS 
5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) 
ROC Area (AUC) Accuracy 
All proteins 0.75±0.14 70.76±12.42 
TAU 0.55±0.16 61.74±13.12 
GFAP 0.80±0.12 70.57±12.22 
NFL 0.50±0.17 50.48±13.46 
MOG 0.63±0.15 62.01±12.46 
GFAP-MOG 0.78±0.13 75.43±12.22 
TAU-GFAP 0.75±0.14 69.41±12.11 
GFAP-NFL 0.78±0.13 75.43±12.22 
GFAP-NFL-MOG 0.75±0.14 69.34±12.81 
NFL-MOG 0.51±0.16 57.76±12.98 
TAU-GFAP-MOG 0.76±0.14 69.35±13.03 
TAU-GFAP-NFL 0.73±0.15 67.86±12.70 
TAU-MOG 0.65±0.16 62.54±13.13 
TAU-NFL 0.69±0.15 63.66±13.07 
TAU-NFL-MOG 0.67±0.16 65.58±13.26 
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Table D.7: Classification Results of CIS vs. MS 
5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) 
ROC Area (AUC) Accuracy 
All proteins 0.78±0.13 75.25±10.70 
TAU 0.60±0.15 68.10±11.60 
GFAP 0.79±0.13 73.67±10.69 
NFL 0.53±0.16 61.48±11.79 
MOG 0.66±0.15 69.73±10.85 
GFAP-MOG 0.82±0.12 76.72±10.52 
TAU-GFAP 0.75±0.14 73.28±10.87 
GFAP-NFL 0.82±0.12 76.72±10.52 
GFAP-NFL-MOG 0.77±0.13 72.79±11.28 
NFL-MOG 0.49±0.15 60.10±10.94 
TAU-GFAP-MOG 0.79±0.13 71.99±11.36 
TAU-GFAP-NFL 0.78±0.13 72.87±11.29 
TAU-MOG 0.68±0.15 67.76±11.32 
TAU-NFL 0.73±0.14 68.38±11.55 
TAU-NFL-MOG 0.69±0.15 71.63±11.32 
Table D.8: Classification Results of CIS vs CIS/RR vs. RRMS 
5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) 
ROC Area (AUC) Accuracy 
All proteins 0.81±0.14 69.87±11.61 
TAU 0.63±0.17 59.00±12.74 
GFAP 0.81±0.13 67.07±11.77 
NFL 0.58±0.19 49.72±13.59 
MOG 0.65±0.16 59.37±12.46 
GFAP-MOG 0.77±0.15 71.26±12.53 
TAU-GFAP 0.78±0.14 67.24±11.59 
GFAP-NFL 0.77±0.15 71.26±12.53 
GFAP-NFL-MOG 0.75±0.15 64.58±12.50 
NFL-MOG 0.53±0.17 54.39±12.72 
TAU-GFAP-MOG 0.78±0.14 67.14±12.72 
TAU-GFAP-NFL 0.80±0.13 66.15±12.24 
TAU-MOG 0.68±0.17 60.92±12.84 
TAU-NFL 0.74±0.15 61.79±12.88 
TAU-NFL-MOG 0.73±0.16 63.94±12.81 
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Table D.9: Classification Results of MS vs. CTRL 
5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) 
ROC Area (AUC) Accuracy 
All proteins 0.97±0.08 94.25±6.44 
TAU 0.84±0.12 77.68±10.87 
GFAP 0.82±0.15 83.51±9.65 
NFL 0.83±0.18 90.94±7.83 
MOG 0.88±0.16 92.35±7.63 
GFAP-MOG 0.90±0.15 91.86±7.69 
TAU-GFAP 0.88±0.13 87.72±9.75 
GFAP-NFL 0.89±0.14 90.52±8.34 
GFAP-NFL-MOG 0.94±0.11 90.99±7.77 
NFL-MOG 0.91±0.14 93.01±7.38 
TAU-GFAP-MOG 0.93±0.12 91.35±7.86 
TAU-GFAP-NFL 0.93±0.11 92.26±7.42 
TAU-MOG 0.90±0.14 92.38±7.77 
TAU-NFL 0.95±0.09 90.74±8.31 
TAU-NFL-MOG 0.94±0.11 93.86±6.53 
Table D.10: Classification Results of MS vs OND 
5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) 
ROC Area (AUC) Accuracy 
All proteins 0.98±0.05 95.80±5.94 
TAU 0.79±0.19 82.97±8.45 
GFAP 0.76±0.25 88.53±8.23 
NFL 0.81±0.28 92.61±7.58 
MOG 0.86±0.28 93.49±7.50 
GFAP-MOG 0.93±0.16 91.05±7.87 
TAU-GFAP 0.84±0.22 87.76±9.36 
GFAP-NFL 0.83±0.24 91.73±7.16 
GFAP-NFL-MOG 0.94±0.16 95.09±6.59 
NFL-MOG 0.90±0.21 95.40±6.62 
TAU-GFAP-MOG 0.94±0.13 90.96±7.98 
TAU-GFAP-NFL 0.94±0.14 94.34±6.57 
TAU-MOG 0.93±0.15 92.15±7.82 
TAU-NFL 0.98±0.06 93.83±7.32 
TAU-NFL-MOG 0.94±0.15 94.95±6.28 
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Table D.11: Classification Results of MS vs. HC 
5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) 
ROC Area (AUC) Accuracy 
All proteins 0.95±0.15 97.64±4.58 
TAU 0.85±0.16 82.50±8.07 
GFAP 0.78±0.25 89.00±7.36 
NFL 0.86±0.21 94.52±6.81 
MOG 0.89±0.21 96.78±5.32 
GFAP-MOG 0.88±0.22 93.66±7.49 
TAU-GFAP 0.86±0.22 90.60±9.29 
GFAP-NFL 0.84±0.26 94.17±7.04 
GFAP-NFL-MOG 0.94±0.15 96.81±5.05 
NFL-MOG 0.94±0.15 95.11±6.46 
TAU-GFAP-MOG 0.89±0.21 93.65±7.49 
TAU-GFAP-NFL 0.89±0.21 96.60±5.24 
TAU-MOG 0.89±0.21 95.52±6.55 
TAU-NFL 0.90±0.21 95.03±6.18 
TAU-NFL-MOG 0.95±0.14 96.65±5.59 
Table D.12: Classification Results of PPMS vs RRMS 
5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) 
ROC Area (AUC) Accuracy 
All proteins 0.95±0.11 95.91±6.85 
TAU 0.77±0.22 87.73±7.63 
GFAP 0.89±0.16 88.02±10.58 
NFL 0.60±0.23 67.78±13.21 
MOG 0.74±0.22 84.31±11.04 
GFAP-MOG 0.95±0.12 92.86±8.52 
TAU-GFAP 0.95±0.11 92.85±8.63 
GFAP-NFL 0.95±0.12 92.86±8.52 
GFAP-NFL-MOG 0.95±0.11 93.54±8.41 
NFL-MOG 0.82±0.21 87.10±10.22 
TAU-GFAP-MOG 0.96±0.11 93.39±8.37 
TAU-GFAP-NFL 0.96±0.11 93.65±8.35 
TAU-MOG 0.93±0.12 89.13±10.51 
TAU-NFL 0.90±0.16 88.02±11.25 
TAU-NFL-MOG 0.93±0.12 91.94±9.43 
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Table D.13: Classification Results of CIS vs MS vs. Control 
5NN 10 fold cross validation, 
1000 run p<0.05 two tailed, 
paired t-test (corrected) 
ROC Area (AUC) Accuracy 
All proteins 0.75±0.13 71.62±10.21 
TAU 0.57±0.14 51.03±11.21 
GFAP 0.74±0.13 64.41±10.41 
NFL 0.47±0.16 56.87±11.17 
MOG 0.62±0.16 66.15±10.56 
GFAP-MOG 0.79±0.13 74.12±10.77 
TAU-GFAP 0.71±0.14 66.76±10.76 
GFAP-NFL 0.73±0.14 64.01±11.18 
GFAP-NFL-MOG 0.75±0.13 70.18±10.61 
NFL-MOG 0.48±0.15 61.11±10.45 
TAU-GFAP-MOG 0.76±0.13 70.17±10.82 
TAU-GFAP-NFL 0.73±0.14 66.97±10.88 
TAU-MOG 0.65±0.15 67.00±10.92 
TAU-NFL 0.66±0.15 65.73±10.93 
TAU-NFL-MOG 0.66±0.15 66.53±10.58 
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APPENDIX E. Results of Classification of Protein Data and Clinical Data 
Table E.1: Classification results of MS patients, CIS patients and Total Control  
group  using       proteins only, PCA Applied to protein data, using all 
features, PCA Applied to all features and using information gain based 
feature selection methods.Applied classification methods are KNN, 
J48(Decision Tree), Random Forest, Adaptive Boosting(AdaBoost M1), 
DECORATE, Bayesian Networks (BayesNet). (10 fold cross 
validation, 1000 run p<0.05 two tailed, paired t-test (corrected))  
MS vs. CTRL vs. CIS 
Knn 
( 5-NN) J48 
Random 
Forest AdaBoost M1 
DECORAT
E BayesNet 
Proteins 
Accuracy % 71.62±10.21  72.27±10.73  69.13±11.21  67.22±9.57  71.51±11.02  71.36±11.29  
AUC 0.75±0.13  0.69±0.16   0.74±0.14  0.74±0.13  0.77±0.14  0.73±0.14  
All 
Proteins- 
PCA 
Accuracy % 
71.18±10.37 67.41±11.48 64.46±11.28 63.89±6.93 66.84±11.38 69.95±9.88 
AUC 
  0.77±0.13 0.66±0.15 0.72±0.14  0.56±0.11 0.69±0.16 0.69±0.13 
All 
Features 
Accuracy % 63.13 ±11.61 70.66 ±10.99 
72.09 
±10.99 67.09 ±9.57 72.23 ±10.90 72.80 ±10.56 
AUC 0.66 ±0.15 0.72 ±0.16 0.81 ±0.12 0.73 ±0.14 0.82 ±0.12 0.76 ±0.13 
All 
Features-
PCA 
Accuracy % 65.17±11.60 64.84±11.61 65.52±11.48   61.52±7.07 61.40± 12.27 60.74± 10.37  
AUC 0.71±0.14 0.67±0.14 0.71±0.14  0.66±0.13 0.70±0.15 0.68±0.14 
Feature 
Selection-
InfoGain 
Accuracy % 68.62±10.83 68.88±10.63  
71.43± 
10.95  67.09± 9.57  70.90±11.04 73.01± 10.51 
AUC 0.74±0.12 0.72±0.15  0.82± 0.12 0.73±0.14 0.82±0.12   0.77±0.13 
Selected 
Features Duration of MS,    EDSS,   OCB,    TAU ,             GFAP,         NFL ,         MOG 
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Table E.2: Classification results CIS patients and Total Control  group  using 
proteins only, PCA Applied to protein data, using all features, PCA 
Applied to all features and using information gain based feature 
selection methods.Applied classification methods are KNN, 
J48(Decision Tree), Random Forest, Adaptive Boosting(AdaBoost M1), 
DECORATE, Bayesian Networks (BayesNet). ). (10 fold cross 
validation, 1000 run p<0.05 two tailed, paired t-test (corrected))  
CIS vs Total CTRL 
kNN 
( 5-NN) J48 
Random 
Forest AdaBoost M1 DECORATE BayesNet 
Proteins 
AUC 0.93±0.09  0.84±0.16  0.87±0.14   0.81±0.20  0.89±0.15   0.86±0.17  
Accuracy 
% 87.31±12.02   83.38±14.18  82.82±13.77  79.78±14.99   83.76±13.85  84.58±13.32  
All 
Proteins- 
PCA AUC  0.93±0.10  0.85±0.15 0.92±0.11  0.91±0.13 0.91±0.12 0.92±0.10 
Accuracy 
%  87.45±12.02  84.47±13.64 83.44±13.28 83.68±12.66 83.39±13.22  81.36±13.79 
All Features 
AUC 0.87 ±0.14  0.79 ±0.19 0.91 ±0.13  0.89 ±0.14 0.90 ±0.14  0.85 ±0.18 
Accuracy 
% 82.29 ±13.96 
 81.86 
±13.73 
 82.93 
±13.07  80.46 ±14.56  83.76 ±13.38 83.41 ±13.75 
All 
Features-
PCA 
AUC  0.84±0.15  0.73±0.18  0.88±0.15   0.86±0.15  0.86±0.17 0.86±0.16 
Accuracy 
%  72.55±16.43 75.25±15.63  
  
82.11±13.39  78.22±14.80   78.66±15.04  82.53±13.88 
Feature 
Selection-
InfoGain 
AUC  0.93±0.09  0.80±0.19  0.88±0.14  0.81±0.18   0.89±0.15  0.86±0.17 
Accuracy 
%  86.06±12.14  82.00±14.55   82.58±13.56  76.83±14.89  82.91±14.17 84.91±13.31 
Selected 
Features MR/T2, Gadolinium Enhancement, TAU, GFAP, NFL, MOG 
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Table E.3: Classification results CIS patients and  OND Control  group 
subset(Other Neurological Diseases)  using proteins only, PCA Applied 
to protein data, using all features, PCA Applied to all features and using 
information gain based feature selection methods.Applied classification 
methods are KNN, J48(Decision Tree), Random Forest, Adaptive 
Boosting(AdaBoost M1), DECORATE, Bayesian Networks 
(BayesNet). ). (10 fold cross validation, 1000 run p<0.05 two tailed, 
paired t-test (corrected)) 
CIS vs OND 
kNN 
( 5-NN) J48 
Random 
Forest 
AdaBoost 
M1 
DECORAT
E BayesNet 
Proteins 
AUC 0.92±0.11  0.74±0.29  0.82±0.21  0.78±0.23  0.80±0.27  0.84±0.25  
Accuracy 
% 82.29±12.31  83.28±14.39  78.93±13.84  77.40±13.90  82.08±14.68  87.52±13.31  
All 
Proteins- 
PCA 
AUC 0.93±0.11    0.80±0.23   0.93±0.13    0.95±0.12   0.91±0.15   0.94±0.11 
Accuracy 
% 82.65±11.79  88.36±12.81  87.47±12.30 89.06±12.06  86.92±13.52  90.91±11.51 
All 
Features 
AUC 0.70 ±0.28 0.59 ±0.37 0.85 ±0.23 0.76 ±0.25 0.84 ±0.25   0.84 ±0.25 
Accuracy 
% 81.35 ±12.14  80.73 ±12.01 84.81 ±12.69  79.27 ±14.13 84.54 ±13.29  87.52 ±13.32 
All 
Features-
PCA 
AUC 0.74±0.26  0.61±0.27  0.72±0.29   0.77±0.27   0.71±0.30   0.44±0.12  
Accuracy 
% 78.75±13.16 76.08±17.82 80.98±11.42   81.79±13.59  78.11±15.60  78.33±10.18 
Feature 
Selection-
InfoGain 
AUC 0.87±0.18 0.80±0.23   0.78±0.23   0.83±0.19  0.86±0.21   0.81±0.21 
Accuracy 
% 87.19±13.61  84.78±13.90   76.42±14.38   78.82±14.42  83.69±14.02  84.90±13.69 
Selected 
Features 
Autoimmune Disease in Self, MOG  
  
 
 
 
 
 
 
 
 
 
 
 
  
 
66 
Table E.4:  Classification results CIS patients and  Healty Control  group subset 
using proteins only, PCA Applied to protein data, using all features, 
PCA Applied to all features and using information gain based feature 
selection methods.Applied classification methods are KNN, 
J48(Decision Tree), Random Forest, Adaptive Boosting(AdaBoost 
M1), DECORATE, Bayesian Networks (BayesNet). ). (10 fold cross 
validation, 1000 run p<0.05 two tailed, paired t-test (corrected))  
CIS vs HC 
kNN 
( 5-NN) J48 
Random 
Forest AdaBoost M1 DECORATE BayesNet 
Proteins 
AUC 0.90±0.17 0.77±0.26 0.82±0.22 0.69±0.33 0.84±0.25 0.86±0.21 
Accuracy 
% 87.79±12.18 86.89±13.20 81.92±14.17 78.30±14.74 83.28±14.77 85.07±13.16 
All 
Proteins- 
PCA AUC 0.87±0.21 0.75±0.33 0.85±0.20 0.90±0.15 0.88±0.19 0.84±0.20 
Accuracy 
% 85.74±11.52 83.46±12.84 83.24±13.54 82.13±13.46 83.54±13.33 82.95±13.26 
All 
Features 
AUC 0.87 ±0.20 0.75 ±0.27 0.93 ±0.18 0.93 ±0.15 0.92 ±0.19 0.96 ±0.10 
Accuracy 
% 84.42 ±14.89 86.96 ±12.36 92.04 ±10.31 89.00 ±13.31 91.54 ±10.80 89.04 ±12.28 
All 
Features-
PCA 
AUC 0.83±0.24 0.83±0.22 0.90±0.21 0.91±0.20 0.89±0.24 0.86±0.24 
Accuracy 
% 76.44±18.11 89.88±12.36 91.57±10.54 91.06±11.60 86.08±14.56 89.07±11.67 
Feature 
Selection-
InfoGain 
AUC 0.94±0.16 0.75±0.27 0.92±0.18 0.96±0.13 0.93±0.18 0.98±0.07 
Accuracy 
% 91.22±11.51 86.99±12.32 91.53±10.70 91.73±11.57 91.98±10.62 89.47±11.72 
Selected 
Features 
Duration of MS, Onset Age, Autoimmune Disease in Self, Autoimmune Disease in Family, 
Atrophy/Cortical, Atrophy/Corpus, Callosum, Gadolinium Enhancement, TAU, NFL, MOG 
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Table E.5: Classification results of CIS patients and  MS patients using proteins 
only, PCA Applied to protein data, using all features, PCA Applied to 
all features and using information gain based feature selection 
methods.Applied classification methods are KNN, J48(Decision Tree), 
Random Forest, Adaptive Boosting(AdaBoost M1), DECORATE, 
Bayesian Networks (BayesNet). ). (10 fold cross validation, 1000 run 
p<0.05 two tailed, paired t-test (corrected))  
MS vs. CIS 
kNN 
( 5-NN) J48 
Random 
Forest 
AdaBoost 
M1 DECORATE BayesNet 
Proteins 
AUC 0.78±0.13 0.72±0.15  0.78±0.13  0.78±0.14  0.77±0.14   0.76±0.13  
Accuracy 
% 75.25±10.70 71.79±10.63  71.64±11.95  74.77±11.45  73.42±10.93  74.36±12.36  
All 
Proteins- 
PCA AUC 
 0.79±0.12   0.66±0.14  0.73±0.14    0.72±0.15   0.72±0.14 0.76±0.13 
Accuracy 
% 
   
74.99±10.68  68.48±12.49  66.25±12.24 70.15±11.64   67.82±11.67 73.13±10.62 
All 
Features 
AUC  0.68 ±0.15 0.73 ±0.16  0.82 ±0.12  0.83 ±0.12 0.82 ±0.12 0.81 ±0.13 
Accuracy 
% 65.09 ±12.55 75.75 ±11.94 75.80 ±11.46 76.51 ±11.15 75.75 ±11.29 77.14 ±11.36 
All 
Features-
PCA 
AUC  0.70±0.14   0.59±0.15   0.68±0.15  0.68±0.14  0.60±0.17  0.49±0.06 
Accuracy 
%  68.75±11.95  61.68±12.56  65.55±12.47   65.35±11.97    61.59±12.55   61.35±7.09 
Feature 
Selection-
InfoGain 
AUC  0.76±0.13  0.78±0.14  0.77±0.14   0.81±0.12 0.82±0.13   0.82±0.12 
Accuracy 
%  71.91±11.39  77.54±10.65   74.30±11.74  75.48±11.28  77.88±10.46  78.31±10.76 
Selected 
Features 
Duration of MS, EDSS, GFAP 
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Table E.6: Classification results of total Control Group and  MS patients using 
proteins only, PCA Applied to protein data, using all features, PCA 
Applied to all features and using information gain based feature 
selection methods.Applied classification methods are KNN, 
J48(Decision Tree), Random Forest, Adaptive Boosting(AdaBoost M1), 
DECORATE, Bayesian Networks (BayesNet). ). (10 fold cross 
validation, 1000 run p<0.05 two tailed, paired t-test (corrected))  
MS vs.total  CTRL 
kNN 
( 5-NN) J48 
Random 
Forest 
AdaBoost 
M1 
DECORAT
E BayesNet 
Proteins 
AUC 0.97±0.08  0.86±0.16  0.93±0.11  0.92±0.14  0.91±0.16  0.91±0.15  
Accuracy 
% 94.25±6.44  92.40±7.62  91.62±8.17  90.49±8.20  93.09±8.03  94.75±6.32  
All Proteins- 
PCA 
AUC 0.98±0.06 0.89±0.16 0.95±0.10 0.97±0.06 0.94±0.10 0.93±0.12 
Accuracy 
% 94.79±5.93  92.01±7.45 92.74±7.41 92.64±7.15 93.19±7.37 93.24±7.65 
All Features 
AUC  0.90 ±0.13 0.82 ±0.18 0.93 ±0.12 0.94 ±0.12  0.93 ±0.12 0.94 ±0.10 
Accuracy 
% 87.97 ±10.02 91.71 ±7.65 92.17 ±7.86  92.29 ±7.99  92.14 ±7.76 93.47 ±7.05 
All Features-
PCA 
AUC 0.85±0.18 0.85±0.15 0.90±0.15  0.88±0.16 0.88±0.17  0.92±0.11 
Accuracy 
% 86.50±9.96 90.66±8.44  92.57±7.21  88.91±8.62  87.99±10.17  90.28±8.11  
Feature 
Selection-
InfoGain 
AUC 0.97±0.06  0.86±0.16  0.94±0.11 0.94±0.12  0.93±0.12 0.94±0.10 
Accuracy 
% 92.93±7.59 92.33±7.75 91.97±7.94 91.04±8.21 92.22±8.09  93.51±7.01 
Selected 
Features MR/T2,          OCB,          TAU,         GFAP,           NFL,             MOG 
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Table E.7:  Classification results of OND (Other Neurological Diseases) Control 
subgroup and  MS patients using proteins only, PCA Applied to 
protein data, using all features, PCA Applied to all features and using 
information gain based feature selection methods.Applied 
classification methods are KNN, J48(Decision Tree), Random Forest, 
Adaptive Boosting(AdaBoost M1), DECORATE, Bayesian Networks 
(BayesNet). ). (10 fold cross validation, 1000 run p<0.05 two tailed, 
paired t-test (corrected))  
MS vs. OND 
kNN 
( 5-NN) J48 
Random 
Forest 
AdaBoost 
M1 DECORATE BayesNet 
Proteins 
AUC 0.98±0.05 0.78±0.29 0.92±0.18 0.85±0.27 0.89±0.23 0.88±0.25 
Accuracy 
% 95.80±5.94 93.17±7.27 93.11±7.62 92.12±7.92 94.25±7.16 95.91±6.38 
All Proteins- 
PCA 
AUC 0.90±0.20 0.77±0.32 0.94±0.16 0.99±0.04 0.92±0.18 0.86±0.19 
Accuracy 
% 96.81±4.97 95.13±6.44 95.27±6.38 95.02±5.91 94.60±6.91 91.95±7.59 
All Features 
AUC 0.78 ±0.23 0.71 ±0.34 0.92 ±0.18 0.88 ±0.24 0.91 ±0.22 0.88 ±0.25 
Accuracy 
% 89.57 ±4.61 92.19 ±7.42 94.54 ±6.68 93.15 ±7.48 94.46 ±6.64 95.81 ±6.42 
All Features-
PCA 
AUC 0.79±0.27 0.84±0.21 0.86±0.23 0.83±0.28 0.83±0.26 0.81±0.24 
Accuracy 
% 90.77±7.57 93.31±7.57 92.54±6.74 90.88±7.66 91.27±8.38 90.53±7.91 
Feature 
Selection-
InfoGain 
AUC 0.98±0.05 0.78±0.29 0.92±0.18 0.85±0.27 0.87±0.26 0.88±0.25 
Accuracy 
% 95.80±5.94 93.17±7.27 93.11±7.62 92.12±7.92 93.97±7.34 95.91±6.38 
Selected 
Features TAU ,GFAP, NFL, MOG 
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Table E.8: Classification results of Healty Control subgroup and  MS patients using 
proteins only, PCA Applied to protein data, using all features, PCA 
Applied to all features and using information gain based feature 
selection methods.Applied classification methods are KNN, 
J48(Decision Tree), Random Forest, Adaptive Boosting(AdaBoost M1), 
DECORATE, Bayesian Networks (BayesNet). ). (10 fold cross 
validation, 1000 run p<0.05 two tailed, paired t-test (corrected))  
MS vs. HC 
kNN 
(5-NN) J48 
Random 
Forest AdaBoost M1 DECORATE BayesNet 
Proteins 
AUC 
0.95±0.15 0.81±0.23 0.94±0.16 0.93±0.19 0.92±0.21 0.93±0.18 
Accuracy 
% 
97.64±4.58 93.62±6.93 94.66±6.51 94.82±6.49 95.41±6.59 97.40±5.01 
All Proteins- 
PCA 
AUC 
0.92±0.18 0.73±0.37 0.93±0.16 0.96±0.10 0.94±0.18 0.90±0.18 
Accuracy 
% 
96.81±5.01 95.01±6.65 94.62±6.75 94.69±6.53 95.21±6.60 93.02±7.28 
All Features 
AUC 
0.91 ±0.17 0.81 ±0.23 0.94 ±0.16 0.96 ±0.11 0.95 ±0.15 0.96 ±0.09 
Accuracy 
% 
91.63 ±9.25 93.58 ±6.98 94.50 ±6.92 95.63 ±6.24 94.30 ±6.69 90.04 ±9.98 
All Features-
PCA 
AUC 
0.87±0.25 0.89±0.20 0.93±0.17 0.95±0.12 0.92±0.22 0.93±0.15 
Accuracy 
% 
93.92±7.80 96.20±6.50 96.00±5.92 93.81±6.90 94.87±7.70 96.60±5.50 
Feature 
Selection-
InfoGain 
AUC 
0.95±0.15 0.81±0.23 0.94±0.16 0.96±0.12 0.95±0.12 0.96±0.09 
Accuracy 
% 
97.53±5.14 93.58±6.99 94.45±6.76 95.80±6.14 93.68±6.89 90.02±10.11 
Selected 
Features 
Onset Age, MS in Family, Autoimmune Disease in Self, Autoimmune Disease in Family, 
EDSS, Atrophy/Cortical, Atrophy/Corpus Callosum, OCB, TAU, GFAP, NFL, MOG 
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Table E.9: Classification results PPMS patients and  RRMS patients using proteins 
only, PCA Applied to protein data, using all features, PCA Applied to 
all features and using information gain based feature selection 
methods.Applied classification methods are KNN, J48(Decision Tree), 
Random Forest, Adaptive Boosting(AdaBoost M1), DECORATE, 
Bayesian Networks (BayesNet). (10 fold cross validation, 1000 run 
p<0.05 two tailed, paired t-test (corrected))  
PP vs. RR 
kNN  
( 5-NN) J48 
Random 
Forest 
AdaBoost 
M1 DECORATE BayesNet 
Proteins 
AUC 0.95±0.11 0.86±0.21  0.92±0.15  0.90±0.16  0.93±0.17  0.93±0.15  
Accuracy 
% 95.91±6.85 91.90±8.78  91.38±9.16  88.88±9.58  92.37±9.07  93.72±8.26  
All 
Proteins- 
PCA AUC 0.95±0.11   0.93±0.11 0.96±0.11 0.96±0.09   0.95±0.13   0.97±0.08 
Accuracy 
% 95.98±6.68 93.03±8.18  93.99±8.14 95.02±7.33 93.51±8.19 95.77±6.63 
All 
Features 
AUC 0.84 ±0.18 0.85 ±0.22 0.93 ±0.14 0.95 ±0.13   0.93 ±0.15 0.94 ±0.14 
Accuracy 
% 80.79 ±8.47  91.12 ±9.30 91.13 ±9.23  91.52 ±9.15  90.96 ±9.30 92.60 ±8.42 
All 
Features-
PCA 
AUC 0.84±0.17   0.72±0.29 0.84±0.20 0.90±0.15    0.81±0.22  0.81±0.19  
Accuracy 
% 84.01±8.49  84.72±10.54  85.86±10.41  
 
85.50±10.29 82.44±12.10 83.58±11.92 
Feature 
Selection-
InfoGain 
AUC  0.93±0.12 0.87±0.19 0.93±0.13   0.94±0.13 0.93±0.14  0.94±0.14 
Accuracy 
% 91.38±9.30 91.79±9.11 91.48±8.98 91.04±9.61 91.21±9.52 92.60±8.42 
Selected 
Features Duration of MS, EDSS, CSF Glucose Level, TAU, GFAP, MOG 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
72 
Table E.10: Classification results CIS patients and  CISRR patients who firsly 
diagnosed as CIS and became RR within 5 years using proteins only, 
PCA Applied to protein data, using all features, PCA Applied to all 
features and using information gain based feature selection 
methods.Applied classification methods are KNN, J48(Decision 
Tree), Random Forest, Adaptive Boosting(AdaBoost M1), 
DECORATE, Bayesian Networks (BayesNet). ). (10 fold cross 
validation, 1000 run p<0.05 two tailed, paired t-test (corrected))  
CIS vs. CISRR 
kNN   
(5-NN) J48 
Random 
Forest 
AdaBoost 
M1 
DECORAT
E BayesNet 
Proteins 
AUC 
0.68±0.32 0.46±0.11 0.73±0.32 0.69±0.37 0.67±0.33 0.50±0.04 
Accuracy % 
83.24±14.19 76.33±12.32 83.01±15.05 82.57±15.80 77.96±16.18 80.36±7.34 
All Proteins- 
PCA 
AUC 
0.67±0.36 0.50±0.00 0.45±0.24 0.50±0.31 0.60±0.35 0.50±0.00 
Accuracy % 
82.15±15.54 88.21±4.04 79.14±11.35 81.42±10.83 77.82±16.74 78.82±6.87 
All Features 
AUC 
0.36 ±0.25 0.67 ±0.27 0.77 ±0.29 0.70 ±0.30 0.80 ±0.28 0.47 ±0.12 
Accuracy % 
80.49 ±6.88 77.39 ±15.20 82.37 ±11.58 77.36 ±16.02 82.34 ±13.97 77.14 
±12.06 
All Features-
PCA 
AUC 
0.62±0.28 0.46±0.19 0.60±0.34 0.69±0.35 0.60±0.35 0.48±0.06 
Accuracy % 
80.50±6.87 69.70±16.61 79.84±10.27 83.82±14.24 74.55±17.24 78.95±9.68 
Feature 
Selection-
InfoGain 
AUC 
0.67±0.30 0.63±0.24 0.74±0.28 0.78±0.31 0.89±0.19 0.49±0.09 
Accuracy % 
80.05±7.70 83.22±13.20 78.82±16.50 80.92±15.73 86.45±12.62 78.91±9.02 
Selected 
Features 
  
Autoimmune Disease in Family,   MR/T1,    OCB,    CSF Protein Level 
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Table E.11: Classification results of RR patients,  CIS patients and  CISRR patients 
who firsly diagnosed as CIS and became RR within 5 years using 
proteins only, PCA Applied to protein data, using all features, PCA 
Applied to all features and using information gain based feature 
selection methods.Applied classification methods are KNN, 
J48(Decision Tree), Random Forest, Adaptive Boosting(AdaBoost M1), 
DECORATE, Bayesian Networks (BayesNet). ). (10 fold cross 
validation, 1000 run p<0.05 two tailed, paired t-test (corrected))  
CIS vs. CISRR vs. RR 
kNN 
(5-NN) J48 
Random 
Forest 
AdaBoost 
M1 DECORATE BayesNet 
Proteins 
AUC 
0.81±0.14 0.68±0.17 0.74±0.16 0.72±0.13 0.75±0.16 0.73±0.12 
Accuracy 
% 
69.87±11.61 62.42±12.38 63.63±13.13 66.25±12.00 62.83±13.00 66.81±12.19 
All Proteins- 
PCA 
AUC 
0.81±0.13 0.75±0.18 0.79±0.15 0.70±0.15 0.78±0.16 0.53±0.08 
Accuracy 
% 
68.47±11.83 67.81±13.74 64.76±12.92 64.48±12.23 65.16±13.09 56.84±8.04 
All Features 
AUC 
0.65 ±0.17 0.70 ±0.16 0.80 ±0.14 0.80 ±0.14 0.79 ±0.14 0.74 ±0.14 
Accuracy 
% 
59.81 ±13.40 63.79 ±12.36 68.72 ±12.33 66.01 ±11.85 67.62 ±12.38 66.57 ±11.65 
All 
Features-
PCA 
AUC 
0.67±0.16 0.51±0.17 0.63±0.18 0.54±0.14 0.63±0.18 0.51±0.13 
Accuracy 
% 
63.81±12.75 51.08±13.24 58.37±12.93 54.74±9.69 54.48±14.08 53.69±8.54 
Feature 
Selection-
InfoGain 
AUC 
0.81±0.13 0.74±0.15 0.76±0.15 0.80±0.13 0.79±0.14 0.74±0.13 
Accuracy 
% 
63.79±12.17 69.87±11.59 64.24±12.92 66.86±12.49 65.01±12.23 67.37±11.48 
Selected 
Features Duration of MS ,     OCB,  GFAP 
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Table E.12: Classification results of RR patients and  CISRR patients who firsly 
diagnosed as CIS and       became RR within 5 years using proteins 
only, PCA Applied to protein data, using all features, PCA Applied to 
all features and using information gain based feature selection 
methods.Applied classification methods are KNN, J48(Decision Tree), 
Random Forest, Adaptive Boosting(AdaBoost M1), DECORATE, 
Bayesian Networks (BayesNet). ). (10 fold cross validation, 1000 run 
p<0.05 two tailed, paired t-test (corrected))  
RR v s. CISRR 
kNN 
( 5-NN) J48 
Random 
Forest 
AdaBoost 
M1 
DECORAT
E BayesNet 
Proteins 
AUC 
0.58±0.23 0.50±0.01 0.68±0.28 0.72±0.29 0.52±0.28 0.50±0.00 
Accuracy % 
87.19±5.25 88.07±4.58 83.58±10.25 85.26±9.55 86.40±7.24 88.21±4.01 
All Proteins- 
PCA 
AUC 
0.60±0.23 0.50±0.00 0.45±0.24 0.50±0.31 0.46±0.25 0.50±0.00 
Accuracy % 
87.01±5.41 88.21±4.04 79.14±11.35 81.42±10.83 86.90±6.06 88.21±4.01 
All Features 
AUC 
0.51 ±0.23 0.62 ±0.22 0.80 ±0.23 0.76 ±0.24 0.78 ±0.24 0.49 ±0.10 
Accuracy % 
87.98 ±4.36 82.62 ±9.71 87.17 ±8.37 86.08 ±8.64 86.94 ±8.49 86.13 ±6.48 
All Features-
PCA 
AUC 
0.60±0.27 0.61±0.25 0.68±0.28 0.66±0.29 0.65±0.30 0.45±0.09 
Accuracy % 
88.21±4.01 81.50±12.27 85.66±8.42 84.68±10.01 83.12±10.97 87.65±5.68 
Feature 
Selection-
InfoGain 
AUC 
0.92±0.12 0.71±0.24 0.88±0.19 0.89±0.16 0.88±0.16 0.49±0.10 
Accuracy % 
89.77±7.00 84.51±9.37 90.49±9.47 89.98±9.27 87.89±9.17 86.13±6.48 
Selected 
Features Duration of MS, MS in Family, Gadolinium Enhancement, CSF Protein Level 
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Table E.13: Classification results of CIS patients and RR patients using proteins 
only, PCA Applied to protein data, using all features, PCA Applied to 
all features and using information gain based feature selection 
methods.Applied classification methods are KNN, J48(Decision Tree), 
Random Forest, Adaptive Boosting(AdaBoost M1), DECORATE, 
Bayesian Networks (BayesNet). ). (10 fold cross validation, 1000 run 
p<0.05 two tailed, paired t-test (corrected))  
RR v s. CIS 
kNN 
( 5-NN) J48 
Random 
Forest 
AdaBoost 
M1 
DECORAT
E BayesNet 
Proteins 
Accuracy % 70.76±12.42 67.40±12.35  67.55±13.19  70.99±12.47  69.31±12.71  72.05±12.77 
AUC 0.75±0.14 0.68±0.16  0.74±0.15  0.75±0.15  0.73±0.15  0.73±0.13 
All Proteins- 
PCA 
Accuracy % 
70.23±12.27 71.63±14.23 64.15±13.43 63.58±13.12 71.87±13.30 63.91±10.77 
AUC 
0.76±0.14 0.67±0.17 0.71±0.15 0.66±0.16  0.72±0.16 0.62±0.12  
All Features 
Accuracy % 63.89 ±13.80 70.21 ±13.02 72.83 ±12.67 73.96 ±12.21 71.95 ±12.65  74.80 ±11.16 
AUC 0.67 ±0.16 0.72 ±0.16 0.80 ±0.13  0.81 ±0.13  0.78 ±0.14 0.78 ±0.13 
All Features-
PCA 
Accuracy % 69.57±13.33  54.79±13.63 60.84±13.98 65.61±13.35  58.77±13.79   57.01±7.72 
AUC 0.72±0.15 0.53±0.16 0.64±0.16  0.69±0.16 0.59±0.17   0.48±0.05 
Feature 
Selection-
InfoGain 
Accuracy % 71.28±12.59 
  
77.00±11.82 72.82±12.72 
  
72.57±12.47 75.35±12.05 
  
75.13±11.15 
AUC 0.80±0.13 0.78±0.14  0.78±0.14    0.79±0.14  0.80±0.13 0.78±0.13 
Selected 
Features Duration of MS, GFAP 
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